Search

Your search keyword '"Adelaida Lacasta"' showing total 31 results
Start Over Author "Adelaida Lacasta"
31 results on '"Adelaida Lacasta"'

1. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

Author

Quintana Lopez, José María, Mañas, Marisa Baré, Bautista, Maximino Redondo, Pérez de la Blanca, Eduardo Briones, Fernández de Larrea Baz, Nerea, Eizaguirre, Cristina Sarasqueta, Martínez, Antonio Escobar, Ruiz, Francisco Rivas, Morales-Suárez-Varela, María M., Blasco Amaro, Juan Antonio, Gonzalez, Isabel del Cura, Madariaga, Inmaculada Arostegui, González, Amaia Bilbao, Hernandez, Nerea González, García-Gutiérrez, Susana, Guerrero, Iratxe Lafuente, Larracoechea, Urko Aguirre, Calzada, Miren Orive, Corral, Josune Martin, Anton-Ladislao, Ane, Torà, Nuria, Pont, Marina, Martínez del Prado, María Purificación, Totorikaguena, Alberto Loizate, Estevez, Ignacio Zabalza, Alustiza, José Errasti, Gimeno García, Antonio Z., Aramburu, Santiago Lázaro, Serrano, Mercè Comas, Enríquez Navascues, José María, Galan, Carlos Placer, Perales, Amaia, Valmaña, Iñaki Urkidi, Erro Azkárate, José María, Lizarribar, Enrique Cormenzana, Muñoa, Adelaida Lacasta, Pibernat, Pep Piera, Cuevas, Elena Campano, Sotelo Gómez, Ana Isabel, Abril, Segundo Gómez, Medina-Cano, F., Alcaide, Julia, Del Rey-Moreno, Arturo, Alcántara, Manuel Jesús, Campo, Rafael, Casalots, Alex, Pericay, Carles, Gil, María José, Pera, Miquel, Collera, Pablo, Espinàs, Josep Alfons, Martínez, Mercedes, Espallargues, Mireia, Almazán, Caridad, Lindenbaum, Paula Dujovne, Fernández-Cebrián, José María, Fernández, Rocío Anula, Mayol Martínez, Julio Ángel, Cid, Ramón Cantero, Labajo, Héctor Guadalajara, Garceau, María Heras, Olmo, Damián García, Montalvo, Mariel Morey, Mar, Javier, Téllez, Teresa, Abitei, Cristina, Padilla-Ruiz, María del Carmen, Rivas-Ruiz, Francisco, Fúnez, Rafael, Pereda, Teresa, Rodrigo, Isabel, Baré, María Luisa, Morales Suárez-Varela, María Manuela, Zabalza, Iñaki, Sánchez del Charco, Matilde, Borrero Martín, Juan José, García del Moral, Raimundo, Escobar, Antonio, Quintana, José María, Aguirre, Urko, and Redondo, Maximino

Published
2019
Full Text
View/download PDF

2. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Thaler, Josef, Greil, Richard, Gaenzer, Johannes, Eisterer, Wolfgang, Tschmelitsch, Joerg, Keil, Felix, Samonigg, Hellmut, Zabernigg, August, Schmid, Franz, Steger, Günther, Steinacher, Robert, Andel, Johannes, Jagdt, Björn, Lang, Alois, Fridrik, Michael, Függer, Reinhold, Hofbauer, Friedrich, Woell, Ewald, Geissler, Dietmar, Lenauer, Alfred, Prager, Manfred, D'Haens, Geert, Demolin, Gauthier, Kerger, Joseph, Deboever, Guido, Ghillebert, Gilbert, Polus, Marc, Van Cutsem, Eric, Kalantari, Hassan Rezaie, Delaunoit, Thierry, Goeminne, Jean Charles, Peeters, Marc, Vergauwe, Philippe, Houbiers, Ghislain, Humblet, Yves, Janssens, Jos, Schrijvers, Dirk, Vanderstraeten, Erik, Van Laethem, Jean-Luc, Vermorken, Jan, Van Daele, Daniel, Ferrante, Michel, Forget, Frederic, Hendlisz, Alain, Yilmaz, Mette, Nielsen, Svend Erik, Vestermark, Lene, Larsen, Jim, Zawadi, Mohamed-Ayman, Bouche, Olivier, Mineur, Laurent, Bennouna-Louridi, Jaafar, Dourthe, Louis Marie, Ychou, Marc, Boucher, Eveline, Taieb, Julien, Pezet, Denis, Desseigne, Francoise, Ducreux, Michel, Texereau, Patrick, Miglianico, Laurent, Rougier, Philippe, Fratte, Serge, Levache, Charles-Briac, Merrouche, Yacine, Ellis, Stephen, Locher, Christophe, Ramee, Jean-Francois, Garnier, Claire, Viret, Frederic, Chauffert, Bruno, Cojean-Zelek, Isabelle, Michel, Pierre, Lecaille, Cedric, Borel, Christian, Seitz, Jean-Francois, Smith, Denis, Lombard-Bohas, Catherine, Andre, Thierry, Gornet, Jean-Marc, Fein, Francine, Coulon-Sfairi, Marie-Aude, Kaminsky, Marie-Christine, Lagasse, Jean-Paul, Luet, Dominique, Etienne, Pierre-Luc, Gasmi, Mohamed, Vanoli, Andre, Nguyen, Suzanne, Aparicio, Thomas, Perrier, Hervé, Stremsdoerfer, Noel, Laplaige, Philippe, Arsene, Dominique, Auby, Dominique, Bedenne, Laurent, Coriat, Romain, Denis, Bernard, Geoffroy, Patrick, Piot, Gilles, Becouarn, Yves, Bordes, Gilbert, Deplanque, Gael, Dupuis, Olivier, Fruge, Frederic, Guimbaud, Rosine, Lecomte, Thierry, Lledo, Gérard, Sobhani, Iradej, Asnacios, Amani, Azzedine, Ahmed, Desauw, Christophe, Galais, Marie-Pierre, Gargot, Dany, Lam, You-Heng, Abakar-Mahamat, Abakar, Berdah, Jean-Francois, Catteau, Sylviane, Clavero-Fabri, Marie-Christine, Codoul, Jean-Francois, Legoux, Jean-Louis, Goldfain, Denis, Guichard, Pierre, Verge, Denis Pere, Provencal, Jocelyne, Vedrenne, Bruno, Brezault-Bonnet, Catherine, Cleau, Denis, Desir, Jean-Paul, Fallik, David, Garcia, Bruno, Gaspard, Marie-Hélène, Genet, Dominique, Hartwig, Johannes, Krummel, Yves, Budnik, Tamara Matysiak, Palascak-Juif, Vanessa, Randrianarivelo, Harizo, Rinaldi, Yves, Aleba, Albert, Darut-Jouve, Ariane, de Gramont, Aimery, Hamon, Herve, Wendehenne, Frederic, Matzdorff, Axel, Stahl, Michael Konrad, Schepp, Wolfgang, Burk, Martin, Mueller, Lothar, Folprecht, Gunnar, Geissler, Michael, Mantovani-Loeffler, Luisa, Hoehler, Thomas, Asperger, Walter, Kroening, Hendrik, von Weikersthal, Ludwig Fischer, Fuxius, Stefan, Groschek, Matthias, Meiler, Johannes, Trarbach, Tanja, Rauh, Jacqueline, Ziegenhagen, Nicolas, Kretzschmar, Albrecht, Graeven, Ullrich, Nusch, Arnd, von Wichert, Goetz, Hofheinz, Ralf-Dieter, Kleber, Gerhard, Schmidt, Karl-Heinz, Vehling-Kaiser, Ursula, Baum, Claudia, Schuette, Jochen, Haag, Georg Martin, Holtkamp, Wilhelm, Potenberg, Jochen, Reiber, Tobias, Schliesser, Georg, Schmoll, Hans-Joachim, Schneider-Kappus, Wolfgang, Abenhardt, Wolfgang, Denzlinger, Claudio, Henning, Jan, Marxsen, Bartscht, Derigs, Hans Guenter, Lambertz, Helmut, Becker-Boost, Ingulf, Caca, Karel, Constantin, Christian, Decker, Thomas, Eschenburg, Henning, Gabius, Sigrun, Hebart, Holger, Hoffmeister, Albrecht, Horst, Heinz-August, Kremers, Stephan, Leithaeuser, Malte, Mueller, Sebastian, Wagner, Siegfried, Daum, Severin, Schlegel, Frank, Stauch, Martina, Heinemann, Volker, Maiello, Evaristo, Latini, Luciano, Zaniboni, Alberto, Amadori, Dino, Aprile, Giuseppe, Barni, Sandro, Mattioli, Rodolfo, Martoni, Andrea, Passalacqua, Rodolfo, Nicolini, Mario, Pasquini, Enzo, Rabbi, Carla, Aitini, Enrico, Ravaioli, Alberto, Barone, Carlo, Biasco, Guido, Tamberi, Stefano, Gambi, Angelo, Verusio, Claudio, Marzola, Marina, Lelli, Giorgio, Boni, Corrado, Cascinu, Stefano, Bidoli, Paolo, Vaghi, Massimo, Cruciani, Giorgio, Di Costanzo, Francesco, Sobrero, Alberto, Mini, Enrico, Petrioli, Roberto, Aglietta, Massimo, Alabiso, Oscar, Capuzzo, Federico, Falcone, Alfredo, Corsi, Domenico Cristi, Labianca, Roberto, Salvagni, Stefania, Chiara, Silvana, Ciuffreda, Libero, Ferraù, Francesco, Giuliani, Francesco, Lonardi, Sara, Gebbia, Nicola, Mantovani, Giovanni, Sanches, Evaristo, Mellidez, Juan Carlos, Santos, Pedro, Freire, Joao, Sarmento, Cristina, Costa, Luis, Pinto, Antonio Moreira, Barroso, Sergio, Santo, Jorge Espirito, Guedes, Fátima, Monteiro, Amélia, Sa, Anabela, Furtado, Irene, Salazar, Ramon, Aguilar, Enrique Aranda, Herrero, Fernando Rivera, Tabernero, Josep, Valera, Javier Sastre, Ayerbes, Manuel Valladares, Batlle, Jaime Feliu, Gil, Silvia, Esteve, Albert Abad, Garcia-Giron, Carlos, Vivanco, Guillermo Lopez, Salvia, Antonia Salud, Orduña, Vicente Alonso, Garcia, Ruth Vera, Gallego, Javier, Sureda, Bartomeu Massuti, Remon, Jordi, Safont Aguilera, Maria Jose, Nogueras, Luis Cirera, Merino, Bernado Queralt, Castro, Cristina Gravalos, de Prado, Purificacion Martinez, Pericay, Carlos Pijaume, Figueiras, Manuel Constenla, Jordan, Inmaculada Guasch, Gome Reina, Maria Jose, Garcia, Amelia Lopez-Ladron, Garcia-Ramos, Antonio Arrivi, Cervantes, Andres, Martos, Carlos Fernandez, Gaspar, Eugenio Marcuello, Montero, Ines Cabezas, Emperador, Pilar Escudero, Carbonero, Ana Leon, Castillo, Manuel Gallen, Garcia, Teresa Garcia, Lopez, Jose Garcia, Flores, Encarnacion Gonzalez, Morales, Monica Guillot, Muñoz, Marta Llanos, Martín, Ana López, Maurel, Joan, Camara, Juan Carlos, Garcia, Rosario Dueñas, Salgado, Mercedes, Busquier, Isabel Hernandez, Ruiz, Teresa Checa, Muñoa, Adelaida Lacasta, Aliguer, Miquel Nogue, de Taranco, Amalia Velasco Ortiz, Ureña, Miguel Mendez, Gaspa, Ferran Losa, Ponce, Jose Juan, Roig, Carlos Bosch, Jimenez, Pedro Valero, Brotons, Antonio Galan, Rodriguez, Santiago Albiol, Martinez, Jose Ales, Ruiz, Liliana Canosa, Ruiz, Margarita Centelles, Bridgewater, John, Glynne-Jones, Rob, Tahir, Saad, Hickish, Tamas, Cassidy, Jim, Samuel, Leslie, Emile, Jean-François, Julié, Catherine, Le Malicot, Karine, Lepage, Come, Dimet, Stéphanie, Boulagnon-Rombi, Camille, Allard, Marc-Antoine, Penault-Llorca, Frédérique, Bennouna, Jaafar, and Laurent-Puig, Pierre

Published
2017
Full Text
View/download PDF

3. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

Author

Teresa Téllez, Cristina Abitei, María del Carmen Padilla-Ruiz, Francisco Rivas-Ruiz, Rafael Fúnez, Teresa Pereda, Isabel Rodrigo, Julia Alcaide, María Luisa Baré, María Manuela Morales Suárez-Varela, Iñaki Zabalza, Matilde Sánchez del Charco, Juan José Borrero Martín, Raimundo García del Moral, Antonio Escobar, José María Quintana, Urko Aguirre, Maximino Redondo, José María Quintana Lopez, Marisa Baré Mañas, Maximino Redondo Bautista, Eduardo Briones Pérez de la Blanca, Nerea Fernández de Larrea Baz, Cristina Sarasqueta Eizaguirre, Antonio Escobar Martínez, Francisco Rivas Ruiz, María M. Morales-Suárez-Varela, Juan Antonio Blasco Amaro, Isabel del Cura Gonzalez, Inmaculada Arostegui Madariaga, Amaia Bilbao González, Nerea González Hernandez, Susana García-Gutiérrez, Iratxe Lafuente Guerrero, Urko Aguirre Larracoechea, Miren Orive Calzada, Josune Martin Corral, Ane Anton-Ladislao, Nuria Torà, Marina Pont, María Purificación Martínez del Prado, Alberto Loizate Totorikaguena, Ignacio Zabalza Estevez, José Errasti Alustiza, Antonio Z. Gimeno García, Santiago Lázaro Aramburu, Mercè Comas Serrano, José María Enríquez Navascues, Carlos Placer Galan, Amaia Perales, Iñaki Urkidi Valmaña, José María Erro Azkárate, Enrique Cormenzana Lizarribar, Adelaida Lacasta Muñoa, Pep Piera Pibernat, Elena Campano Cuevas, Ana Isabel Sotelo Gómez, Segundo Gómez Abril, F. Medina-Cano, Arturo Del Rey-Moreno, Manuel Jesús Alcántara, Rafael Campo, Alex Casalots, Carles Pericay, María José Gil, Miquel Pera, Pablo Collera, Josep Alfons Espinàs, Mercedes Martínez, Mireia Espallargues, Caridad Almazán, Paula Dujovne Lindenbaum, José María Fernández-Cebrián, Rocío Anula Fernández, Julio Ángel Mayol Martínez, Ramón Cantero Cid, Héctor Guadalajara Labajo, María Heras Garceau, Damián García Olmo, Mariel Morey Montalvo, Javier Mar, European Commission, Instituto de Salud Carlos III, and Red de Investigación en Servicios de Salud en Enfermedades Crónicas (España)

Subjects
Male, medicine.medical_specialty, Survival, Colorectal cancer, Perineural invasion, Asymptomatic, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Biomarkers, Tumor, Humans, Mass Screening, Medicine, Prospective Studies, Colorectal carcinomas, 030212 general & internal medicine, Stage (cooking), Prospective cohort study, Early Detection of Cancer, Aged, Neoplasm Staging, Biological markers, business.industry, Incidence, General Medicine, Middle Aged, medicine.disease, Immunohistochemistry, Survival Rate, Oncology, Spain, 030220 oncology & carcinogenesis, Cohort, Screening, T-stage, Female, Surgery, medicine.symptom, Colorectal Neoplasms, business, Body mass index, Follow-Up Studies
Abstract

REDISSEC-CARESS/CCR group., [Introduction] Few studies have been conducted to establish the relationship between colorectal cancer screening programmes and survival adjusting by stage and, to determine whether there are differences, at a biological level, between the tumours of asymptomatic and symptomatic patients. Accordingly, the aim of this study is to evaluate clinical, biological and survival differences between symptomatic colorectal tumours and those detected by screening., [Study method] A prospective cohort study was performed of patients subjected to surgical intervention during the period 2010–2012, at different hospitals in Spain. In every case, clinical, pathological, biological and survival-related variables were obtained., [Results] A total of 2634 patients from the CARESS-CCR cohort were analysed; of these, 220 were diagnosed through screening. The asymptomatic patients were younger, had a higher Body Mass Index (BMI), a lower degree of perineural invasion and a less advanced T stage and nodular stage, and the tumour was frequently located on the right side of the colon. All of these differences were statistically significant. The serum tumour marker carbohydrate antigen 19.9 (CA 19.9) was found more frequently in the symptomatic patients (p, [Conclusions] The detection method employed influenced the survival of patients with colorectal cancer and there were no significant biological differences between the study groups., This research was partially supported by grants from REDISSEC (RD12/0001/0010 and RD16/0001/0006), Instituto de Salud Carlos III (PI 09/00910, PI 13/00013, PI 18/01181) and the European Regional Development Fund.

Published
2019

4. Outcomes of open versus laparoscopic surgery in patients with colon cancer

Author

José M. Quintana, Ane Antón-Ladisla, Nerea González, Santiago Lázaro, Marisa Baré, Nerea Fernández de Larrea, Maximino Redondo, Eduardo Briones, Antonio Escobar, Cristina Sarasqueta, Susana García-Gutierrez, Jose María Quintana López, Marisa Baré Mañas, Maximino Redondo Bautista, Eduardo Briones Pérez de la Blanca, Nerea Fernández de Larrea Baz, Cristina Sarasqueta Eizaguirre, Antonio Escobar Martínez, Francisco Rivas Ruiz, Maria M. Morales-Suárez-Varela, Juan Antonio Blasco Amaro, Isabel del Cura González, Inmaculada Arostegui Madariaga, Amaia Bilbao González, Nerea González Hernández, Susana García-Gutiérrez, Iratxe Lafuente Guerrero, Urko Aguirre Larracoechea, Miren Orive Calzada, Josune Martin Corral, Ane Antón-Ladislao, Núria Torà, Marina Pont, María Purificación Martínez del Prado, Alberto Loizate Totorikaguena, Ignacio Zabalza Estévez, José Errasti Alustiza, Antonio Z. Gimeno García, Santiago Lázaro Aramburu, Mercè Comas Serrano, Jose María Enríquez Navascues, Carlos Placer Galán, Amaia Perales, Iñaki Urkidi Valmaña, Jose María Erro Azkárate, Enrique Cormenzana Lizarribar, Adelaida Lacasta Muñoa, Pep Piera Pibernat, Elena Campano Cuevas, Ana Isabel Sotelo Gómez, Segundo Gómez-Abril, F. Medina-Cano, Julia Alcaide, Arturo Del Rey-Moreno, Manuel Jesús Alcántara, Rafael Campo, Alex Casalots, Carles Pericay, Maria José Gil, Miquel Pera, Pablo Collera, Josep Alfons Espinàs, Mercedes Martínez, Mireia Espallargues, Caridad Almazán, Paula Dujovne Lindenbaum, José María Fernández-Cebrián, Rocío Anula Fernández, Julio Ángel Mayol Martínez, Ramón Cantero Cid, Héctor Guadalajara Labajo, María Heras Garceau, Damián García Olmo, Mariel Morey Montalvo, and Javier Mar

Subjects
Male, Reoperation, Laparoscopic surgery, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Hospital Anxiety and Depression Scale, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, In patient, Prospective Studies, 030212 general & internal medicine, Propensity Score, Prospective cohort study, Colectomy, Aged, business.industry, General surgery, Open surgery, General Medicine, Length of Stay, medicine.disease, Survival Rate, Treatment Outcome, Oncology, Elective Surgical Procedures, Spain, 030220 oncology & carcinogenesis, Colonic Neoplasms, Propensity score matching, Female, Laparoscopy, Surgery, Complication, business, Follow-Up Studies
Abstract

Objective There is limited information on health service use or patient-reported outcomes when comparing the effectiveness of laparoscopic with that of open surgery. The aim was to compare the effectiveness of laparoscopic with that of open surgery up to 2 years after intervention in patients with colon cancer. Methods Prospective cohort study of patients with colon cancer who underwent surgery (laparoscopic or open surgery) between June 2010 and December 2012, at 22 hospitals. Main outcomes of the study were mortality, complications, reoperation, readmission, and patient-reported outcome measures (PROMs), as measured using the Hospital Anxiety and Depression Scale, Duke-UNC, EuroQol-5D, and European Organisation for Research and Treatment of Cancer-Q30 and Q29 at baseline, and 30 days and 1 and 2 years after surgery. Multivariable multilevel logistic regression and generalized linear models were used in analyses after adjusting for specific propensity scores developed for each outcome and time point. Results In the multivariable analysis, the complication rates up to 30 days (infectious, surgical, and medical) and 1 year (surgical), and readmission rate at 30 days and at 2 years were higher among patients who underwent open surgery than among those who underwent laparoscopic surgery. There were no differences between the two surgical approaches in all other parameters assessed and in changes of all PROMs. Conclusions Though in most outcomes both surgical approaches provide similar results up to 2 years after intervention, still the rates of some complications and readmission, mainly up to 30 days, are higher in open surgery. ClinicalTrials.gov Identifier NCT02488161 .

Published
2018

5. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

Author

José Luis Lavín, Maite G. Fernandez-Barrena, Alvaro Santos-Laso, Jesper B. Andersen, Mauro D'Amato, Robert C. Huebert, Nidhi Jalan-Sakrikar, Kristen M. Thelen, Adelaida Lacasta, Gregory J. Gores, Aitor Esparza-Baquer, Oihane Erice, Elisa Lozano, Ana M. Aransay, Oscar Briz, Colm J O'Rourke, Luis Bujanda, Ander Matheu, Sergio A. Gradilone, Maite Merino-Azpitarte, Raul Jimenez-Agüero, Jose J.G. Marin, Marco Marzioni, Jesus M. Banales, and Maria J. Perugorria

Subjects
0301 basic medicine, Pathology, medicine.medical_specialty, animal structures, Cellular differentiation, Biology, Article, Cholangiocyte, Cholangiocarcinoma, Mice, 03 medical and health sciences, Gene expression, SOXF Transcription Factors, medicine, Animals, Humans, Gene silencing, Epigenetics, Gene knockdown, Hepatology, Tumor Suppressor Proteins, Wnt signaling pathway, Cell Differentiation, Gene Expression Regulation, Neoplastic, 030104 developmental biology, Bile Duct Neoplasms, embryonic structures, DNA methylation, Cancer research, Bile Ducts
Abstract

Background & Aims Cholangiocarcinoma (CCA) is a biliary malignancy linked to genetic and epigenetic abnormalities, such as hypermethylation of SOX17 promoter. Here, the role of SOX17 in cholangiocyte differentiation and cholangiocarcinogenesis was studied. Methods SOX17 expression/function was evaluated along the differentiation of human induced pluripotent stem cells (iPSC) into cholangiocytes, in the dedifferentiation process of normal human cholangiocytes (NHC) in culture and in cholangiocarcinogenesis. Lentiviruses for SOX17 overexpression or knockdown were used. Gene expression and DNA methylation profiling were performed. Results SOX17 expression is induced in the last stage of cholangiocyte differentiation from iPSC and regulates the acquisition of biliary markers. SOX17 becomes downregulated in NHC undergoing dedifferentiation; experimental SOX17 knockdown in differentiated NHC downregulated biliary markers and promoted baseline and Wnt-dependent proliferation. SOX17 expression is lower in human CCA than in healthy tissue, which correlates with worse survival after tumor resection. In CCA cells, SOX17 overexpression decreased their tumorigenic capacity in murine xenograft models, which was related to increased oxidative stress and apoptosis. In contrast, SOX17 overexpression in NHC did not affect their survival but inhibited their baseline proliferation. In CCA cells, SOX17 inhibited migration, anchorage-independent growth and Wnt/β-catenin-dependent proliferation, and restored the expression of biliary markers and primary cilium length. In human CCA, SOX17 promoter was found hypermethylated and its expression inversely correlates with the methylation grade. In NHC, Wnt3a decreased SOX17 expression in a DNMT-dependent manner, whereas in CCA, DNMT1 inhibition or silencing upregulated SOX17 . Conclusions SOX17 regulates the differentiation and maintenance of the biliary phenotype and functions as a tumor suppressor for CCA, being a potential prognostic marker and a promising therapeutic target. Lay summary Understanding the molecular mechanisms involved in the pathogenesis of CCA is key in finding new valuable diagnostic and prognostic biomarkers, as well as therapeutic targets. This study provides evidence that SOX17 regulates the differentiation and maintenance of the biliary phenotype, and its downregulation promotes their tumorigenic transformation. SOX17 acts as a tumor suppressor in CCA and its genetic, molecular and/or pharmacological restoration may represent a new promising therapeutic strategy. Moreover, SOX17 expression correlates with the outcome of patients after tumor resection, being a potential prognostic biomarker.

Published
2017

6. Resultados de la radioterapia de ciclo corto seguida de cirugía radical en el cáncer de recto: estudio unicéntrico y observacional a largo plazo

Author

Mikel Osorio, Garazi Elorza, Yolanda Saralegui, José María Enríquez-Navascués, Maddi Garmendia, Juan Pablo Ciria, Adelaida Lacasta, and Carlos Placer

Subjects
Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, 030220 oncology & carcinogenesis, Medicine, Surgery, 030230 surgery, business
Abstract

Resumen Introduccion La radioterapia preoperatoria corta (RTC) para el tratamiento del cancer de recto (CR) ha sido poco utilizada en Espana. El objetivo del presente trabajo es describir los resultados oncologicos tras tratamiento con RTC y cirugia por CR. Metodos Estudio retrospectivo que incluye una serie consecutiva de pacientes tratados por CR (1999-2012). Se recogieron datos epidemiologicos, estadificacion, complicaciones de la RTC, intervalo RTC-cirugia, abordaje quirurgico, tasa de dehiscencia de anastomosis o herida perineal e histologicos (grado de regresion y estadificacion). Se analizan la supervivencia global, supervivencia libre de enfermedad, tasa de recurrencia local e incidencia de toxicidad, respuesta y complicaciones del tratamiento combinado con RTC y cirugia. Resultados De 1.229 pacientes tratados, 209 pacientes recibieron RTC y cirugia. La mediana de seguimiento fue de 6,2 anos. La edad media fue de 68 anos y el 66% fueron hombres. El 88% eran cT3-4 y el 44% cN+. Un total de 17 pacientes (8,1%) tenian metastasis sincronas resecables. La toxicidad aguda y cronica por RTC fue inferior al 5%. En el 75% de los pacientes el intervalo RTC-cirugia fue inferior a 15 dias y en el 9%, superior a 4 semanas. Fueron 7 los pacientes (3,3%) que presentaron respuesta completa. La mediana de supervivencia fue de casi 10 anos. Nueve (4,3%) pacientes presentaron una recurrencia local. La supervivencia global a 5, 10 y 15 anos fue del 67,8, 49,2 y 37,5%, respectivamente. La supervivencia libre de enfermedad a 5, 10 y 15 anos fue del 66,1; 47,1 y 33%, respectivamente. Conclusiones Los resultados se comparan favorablemente con las series historicas multicentricas. La RTC ofrece ciertas ventajas que pueden ampliarse incrementando el intervalo RTC-cirugia o si se intercala con quimioterapia secuencial.

Published
2017

7. 1174P RESUNET (GETNE-2016-01): A phase II study to evaluate the efficacy and safety of the rechallenge with sunitinib in G1/G2 pancreatic neuroendocrine tumours (pNET). A Spanish Task Force Group in neuroendocrine and endocrine tumours (GETNE) study

Author

Rocio Garcia-Carbonero, R. Yaya Tur, Enrique Grande, I. Gallegos, J. Capdevila Castillón, P. Espinosa-Olarte, A.O. Castillo Trujillo, Robinson Rodríguez, R. Serrano, Adelaida Lacasta, Teresa Alonso, A. Bujedo Martinez, M. Benavent, Pilar Jiménez, J. Molina Cerrillo, J. Hernando, and Agustín Carmona

Subjects
Oncology, medicine.medical_specialty, Sunitinib, business.industry, Task force, Internal medicine, medicine, Endocrine system, Phases of clinical research, Hematology, business, medicine.drug
Published
2020

8. Biological and prognostic differences between symptomatic colorectal carcinomas and those detected by screening

Author

Téllez, Teresa, primary, Abitei, Cristina, additional, Padilla-Ruiz, María del Carmen, additional, Rivas-Ruiz, Francisco, additional, Fúnez, Rafael, additional, Pereda, Teresa, additional, Rodrigo, Isabel, additional, Alcaide, Julia, additional, Baré, María Luisa, additional, Morales Suárez-Varela, María Manuela, additional, Zabalza, Iñaki, additional, Sánchez del Charco, Matilde, additional, Borrero Martín, Juan José, additional, García del Moral, Raimundo, additional, Escobar, Antonio, additional, Quintana, José María, additional, Aguirre, Urko, additional, Redondo, Maximino, additional, Quintana Lopez, José María, additional, Mañas, Marisa Baré, additional, Bautista, Maximino Redondo, additional, Pérez de la Blanca, Eduardo Briones, additional, Fernández de Larrea Baz, Nerea, additional, Eizaguirre, Cristina Sarasqueta, additional, Martínez, Antonio Escobar, additional, Ruiz, Francisco Rivas, additional, Morales-Suárez-Varela, María M., additional, Blasco Amaro, Juan Antonio, additional, Gonzalez, Isabel del Cura, additional, Madariaga, Inmaculada Arostegui, additional, González, Amaia Bilbao, additional, Hernandez, Nerea González, additional, García-Gutiérrez, Susana, additional, Guerrero, Iratxe Lafuente, additional, Larracoechea, Urko Aguirre, additional, Calzada, Miren Orive, additional, Corral, Josune Martin, additional, Anton-Ladislao, Ane, additional, Torà, Nuria, additional, Pont, Marina, additional, Martínez del Prado, María Purificación, additional, Totorikaguena, Alberto Loizate, additional, Estevez, Ignacio Zabalza, additional, Alustiza, José Errasti, additional, Gimeno García, Antonio Z., additional, Aramburu, Santiago Lázaro, additional, Serrano, Mercè Comas, additional, Enríquez Navascues, José María, additional, Galan, Carlos Placer, additional, Perales, Amaia, additional, Valmaña, Iñaki Urkidi, additional, Erro Azkárate, José María, additional, Lizarribar, Enrique Cormenzana, additional, Muñoa, Adelaida Lacasta, additional, Pibernat, Pep Piera, additional, Cuevas, Elena Campano, additional, Sotelo Gómez, Ana Isabel, additional, Abril, Segundo Gómez, additional, Medina-Cano, F., additional, Del Rey-Moreno, Arturo, additional, Alcántara, Manuel Jesús, additional, Campo, Rafael, additional, Casalots, Alex, additional, Pericay, Carles, additional, Gil, María José, additional, Pera, Miquel, additional, Collera, Pablo, additional, Espinàs, Josep Alfons, additional, Martínez, Mercedes, additional, Espallargues, Mireia, additional, Almazán, Caridad, additional, Lindenbaum, Paula Dujovne, additional, Fernández-Cebrián, José María, additional, Fernández, Rocío Anula, additional, Mayol Martínez, Julio Ángel, additional, Cid, Ramón Cantero, additional, Labajo, Héctor Guadalajara, additional, Garceau, María Heras, additional, Olmo, Damián García, additional, Montalvo, Mariel Morey, additional, and Mar, Javier, additional

Published
2019
Full Text
View/download PDF

9. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Jean-François Emile, Catherine Julié, Karine Le Malicot, Come Lepage, Josep Tabernero, Enrico Mini, Gunnar Folprecht, Jean-Luc Van Laethem, Stéphanie Dimet, Camille Boulagnon-Rombi, Marc-Antoine Allard, Frédérique Penault-Llorca, Jaafar Bennouna, Pierre Laurent-Puig, Julien Taieb, Josef Thaler, Richard Greil, Johannes Gaenzer, Wolfgang Eisterer, Joerg Tschmelitsch, Felix Keil, Hellmut Samonigg, August Zabernigg, Franz Schmid, Günther Steger, Robert Steinacher, Johannes Andel, Björn Jagdt, Alois Lang, Michael Fridrik, Reinhold Függer, Friedrich Hofbauer, Ewald Woell, Dietmar Geissler, Alfred Lenauer, Manfred Prager, Geert D'Haens, Gauthier Demolin, Joseph Kerger, Guido Deboever, Gilbert Ghillebert, Marc Polus, Eric Van Cutsem, Hassan Rezaie Kalantari, Thierry Delaunoit, Jean Charles Goeminne, Marc Peeters, Philippe Vergauwe, Ghislain Houbiers, Yves Humblet, Jos Janssens, Dirk Schrijvers, Erik Vanderstraeten, Jan Vermorken, Daniel Van Daele, Michel Ferrante, Frederic Forget, Alain Hendlisz, Mette Yilmaz, Svend Erik Nielsen, Lene Vestermark, Jim Larsen, Mohamed-Ayman Zawadi, Olivier Bouche, Laurent Mineur, Jaafar Bennouna-Louridi, Louis Marie Dourthe, Marc Ychou, Eveline Boucher, Denis Pezet, Francoise Desseigne, Michel Ducreux, Patrick Texereau, Laurent Miglianico, Philippe Rougier, Serge Fratte, Charles-Briac Levache, Yacine Merrouche, Stephen Ellis, Christophe Locher, Jean-Francois Ramee, Claire Garnier, Frederic Viret, Bruno Chauffert, Isabelle Cojean-Zelek, Pierre Michel, Cedric Lecaille, Christian Borel, Jean-Francois Seitz, Denis Smith, Catherine Lombard-Bohas, Thierry Andre, Jean-Marc Gornet, Francine Fein, Marie-Aude Coulon-Sfairi, Marie-Christine Kaminsky, Jean-Paul Lagasse, Dominique Luet, Pierre-Luc Etienne, Mohamed Gasmi, Andre Vanoli, Suzanne Nguyen, Thomas Aparicio, Hervé Perrier, Noel Stremsdoerfer, Philippe Laplaige, Dominique Arsene, Dominique Auby, Laurent Bedenne, Romain Coriat, Bernard Denis, Patrick Geoffroy, Gilles Piot, Yves Becouarn, Gilbert Bordes, Gael Deplanque, Olivier Dupuis, Frederic Fruge, Rosine Guimbaud, Thierry Lecomte, Gérard Lledo, Iradej Sobhani, Amani Asnacios, Ahmed Azzedine, Christophe Desauw, Marie-Pierre Galais, Dany Gargot, You-Heng Lam, Abakar Abakar-Mahamat, Jean-Francois Berdah, Sylviane Catteau, Marie-Christine Clavero-Fabri, Jean-Francois Codoul, Jean-Louis Legoux, Denis Goldfain, Pierre Guichard, Denis Pere Verge, Jocelyne Provencal, Bruno Vedrenne, Catherine Brezault-Bonnet, Denis Cleau, Jean-Paul Desir, David Fallik, Bruno Garcia, Marie-Hélène Gaspard, Dominique Genet, Johannes Hartwig, Yves Krummel, Tamara Matysiak Budnik, Vanessa Palascak-Juif, Harizo Randrianarivelo, Yves Rinaldi, Albert Aleba, Ariane Darut-Jouve, Aimery de Gramont, Herve Hamon, Frederic Wendehenne, Axel Matzdorff, Michael Konrad Stahl, Wolfgang Schepp, Martin Burk, Lothar Mueller, Michael Geissler, Luisa Mantovani-Loeffler, Thomas Hoehler, Walter Asperger, Hendrik Kroening, Ludwig Fischer von Weikersthal, Stefan Fuxius, Matthias Groschek, Johannes Meiler, Tanja Trarbach, Jacqueline Rauh, Nicolas Ziegenhagen, Albrecht Kretzschmar, Ullrich Graeven, Arnd Nusch, Goetz von Wichert, Ralf-Dieter Hofheinz, Gerhard Kleber, Karl-Heinz Schmidt, Ursula Vehling-Kaiser, Claudia Baum, Jochen Schuette, Georg Martin Haag, Wilhelm Holtkamp, Jochen Potenberg, Tobias Reiber, Georg Schliesser, Hans-Joachim Schmoll, Wolfgang Schneider-Kappus, Wolfgang Abenhardt, Claudio Denzlinger, Jan Henning, Bartscht Marxsen, Hans Guenter Derigs, Helmut Lambertz, Ingulf Becker-Boost, Karel Caca, Christian Constantin, Thomas Decker, Henning Eschenburg, Sigrun Gabius, Holger Hebart, Albrecht Hoffmeister, Heinz-August Horst, Stephan Kremers, Malte Leithaeuser, Sebastian Mueller, Siegfried Wagner, Severin Daum, Frank Schlegel, Martina Stauch, Volker Heinemann, Evaristo Maiello, Luciano Latini, Alberto Zaniboni, Dino Amadori, Giuseppe Aprile, Sandro Barni, Rodolfo Mattioli, Andrea Martoni, Rodolfo Passalacqua, Mario Nicolini, Enzo Pasquini, Carla Rabbi, Enrico Aitini, Alberto Ravaioli, Carlo Barone, Guido Biasco, Stefano Tamberi, Angelo Gambi, Claudio Verusio, Marina Marzola, Giorgio Lelli, Corrado Boni, Stefano Cascinu, Paolo Bidoli, Massimo Vaghi, Giorgio Cruciani, Francesco Di Costanzo, Alberto Sobrero, Roberto Petrioli, Massimo Aglietta, Oscar Alabiso, Federico Capuzzo, Alfredo Falcone, Domenico Cristi Corsi, Roberto Labianca, Stefania Salvagni, Silvana Chiara, Libero Ciuffreda, Francesco Ferraù, Francesco Giuliani, Sara Lonardi, Nicola Gebbia, Giovanni Mantovani, Evaristo Sanches, Juan Carlos Mellidez, Pedro Santos, Joao Freire, Cristina Sarmento, Luis Costa, Antonio Moreira Pinto, Sergio Barroso, Jorge Espirito Santo, Fátima Guedes, Amélia Monteiro, Anabela Sa, Irene Furtado, Ramon Salazar, Enrique Aranda Aguilar, Fernando Rivera Herrero, Javier Sastre Valera, Manuel Valladares Ayerbes, Jaime Feliu Batlle, Silvia Gil, Albert Abad Esteve, Carlos Garcia-Giron, Guillermo Lopez Vivanco, Antonia Salud Salvia, Vicente Alonso Orduña, Ruth Vera Garcia, Javier Gallego, Bartomeu Massuti Sureda, Jordi Remon, Maria Jose Safont Aguilera, Luis Cirera Nogueras, Bernado Queralt Merino, Cristina Gravalos Castro, Purificacion Martinez de Prado, Carlos Pijaume Pericay, Manuel Constenla Figueiras, Inmaculada Guasch Jordan, Maria Jose Gome Reina, Amelia Lopez-Ladron Garcia, Antonio Arrivi Garcia-Ramos, Andres Cervantes, Carlos Fernandez Martos, Eugenio Marcuello Gaspar, Ines Cabezas Montero, Pilar Escudero Emperador, Ana Leon Carbonero, Manuel Gallen Castillo, Teresa Garcia Garcia, Jose Garcia Lopez, Encarnacion Gonzalez Flores, Monica Guillot Morales, Marta Llanos Muñoz, Ana López Martín, Joan Maurel, Juan Carlos Camara, Rosario Dueñas Garcia, Mercedes Salgado, Isabel Hernandez Busquier, Teresa Checa Ruiz, Adelaida Lacasta Muñoa, Miquel Nogue Aliguer, Amalia Velasco Ortiz de Taranco, Miguel Mendez Ureña, Ferran Losa Gaspa, Jose Juan Ponce, Carlos Bosch Roig, Pedro Valero Jimenez, Antonio Galan Brotons, Santiago Albiol Rodriguez, Jose Ales Martinez, Liliana Canosa Ruiz, Margarita Centelles Ruiz, John Bridgewater, Rob Glynne-Jones, Saad Tahir, Tamas Hickish, Jim Cassidy, Leslie Samuel, UE 1373 Fourrages Environnement Ruminants Lusignan, Institut National de la Recherche Agronomique ( INRA ) -Physiologie Animale et Systèmes d'Elevage ( PHASE ) -Environnement et Agronomie ( E.A. ) -Biologie et Amélioration des Plantes ( BAP ) -Fourrages Environnement Ruminants Lusignan ( FERLUS ), Service de pathologie [CHU Ambroise Paré], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Ambroise Paré, Service de Biostatistique, Fédération Francophone de la Cancérologie Digestive, FFCD, Lipides - Nutrition - Cancer [Dijon - U1231] ( LNC ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'hépato-gastroentérologie et cancérologie digestive (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Vall d'Hebron University Hospital [Barcelona], Dpt of Internal Medicine, Section of Immunoallergology and Respiratory [Florence] Diseases, University of Florence, Carl Gustav Carus University Hospital, Erasme Hospital, Brussels, Centre Hepato-Biliaire, AP-HP Hôpital Paul Brousse, Modèles de Cellules Souches Malignes et Thérapeutiques, Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Imagerie Moléculaire et Stratégies Théranostiques - Clermont Auvergne ( IMoST ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Clermont Auvergne ( UCA ), Institut de cancérologie de l'Ouest - Nantes ( ICO Nantes ), CRLCC Paul Papin-CRLCC René Gauducheau, Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers ( CRCINA ), Université d'Angers ( UA ) -Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche en Santé de l'Université de Nantes ( IRS-UN ) -Centre hospitalier universitaire de Nantes ( CHU Nantes ), Université de Nantes ( UN ), Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique ( MEPPOT - U1147 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Klinikum Wels Grieskirchen, Oncology department [Salzburg], Salzburger Landesklinikum - Uniklinikum Salzburg ( SALK ), Institute of Chemical Reaction Engineering, Hamburg University of Technology, Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung ( AWI ), Department of Medical Oncology, Medical University Vienna, Department of Internal Medicine, Hospital of Steyr, Department Internal Medicine 3, Centre for Hematology and Medical Oncology, General Hospital Linz, Department Medicine LKH, Institut für Festköperfirschung, Institut des Sciences Moléculaires de Marseille ( ISM2 ), Centre National de la Recherche Scientifique ( CNRS ) -Ecole Centrale de Marseille ( ECM ) -Aix Marseille Université ( AMU ), University Hospitals Leuven [Leuven], Katholieke Universiteit Leuven ( KU Leuven ), Pharmacology and Toxicology, Ahvaz Jundishapur University of Medical Sciences, Institut de Biologie Computationnelle ( IBC ), Centre de Coopération Internationale en Recherche Agronomique pour le Développement ( CIRAD ) -Institut National de la Recherche Agronomique ( INRA ) -Institut National de Recherche en Informatique et en Automatique ( Inria ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut des Sciences Moléculaires ( ISM ), Université Montesquieu - Bordeaux 4-Université Sciences et Technologies - Bordeaux 1-École Nationale Supérieure de Chimie et de Physique de Bordeaux (ENSCPB)-Centre National de la Recherche Scientifique ( CNRS ), Faculty of Veterinary Medicine, Ghent University [Belgium] ( UGENT ), Medical Oncology, Antwerp University Hospital [Edegem], Recombinaison et Expression Génétique, Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier de L'Ardenne (Libramont), Department of Cardiology [Sivas, Turkey], Cumhuriyet University [Sivas, Turkey], Department of Earth Sciences, Durham University, Department of Oncology, Rigshospitalet [Copenhagen], Odense Hospital, CP Kelco ApS, Centre Hospitalier Universitaire de Reims ( CHU Reims ), Institut de Recherche en Cancérologie de Montpellier ( IRCM - U1194 Inserm - UM ), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Université du Québec à Montréal ( UQAM ), Université Panthéon-Sorbonne ( UP1 ), École nationale supérieure d'architecture de Nantes ( ENSA Nantes ), Department of Hepatogastroenterology and Oncology, Hopital Ambroise Pare, 9, Avenue Charles de Gaulle, 92104, Boulogne Cedex, France., Hôpital Ambroise Paré, CH Belfort-Montbéliard, Polyclinique Francheville, Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne ( CHU de Saint-Etienne ), Centre Hospitalier de Meaux, Service d'hématologie, Clinique Catherine de Sienne, Unité de recherche sur les Biopolymères, Interactions Assemblages ( BIA ), Institut National de la Recherche Agronomique ( INRA ), Université de la Méditerranée - Aix-Marseille 2, Centre hospitalier universitaire d'Amiens ( CHU Amiens-Picardie ), CHU Amiens-Picardie, Pôle oncologie médicale, Hôpital des Diaconesses, Génétique du cancer et des maladies neuropsychiatriques ( GMFC ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Bretagne Occidentale - École de sages-femmes ( UBO UFR MSS ESF ), Université de Brest ( UBO ) -Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Service d'oncologie digestive et hépato-gastro-entérologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Service d'Oncologie Médicale [CHU Saint -Antoine], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Centre de Recherche Saint-Antoine ( CR Saint-Antoine ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ), Service Gastro-Entérologie, CHU Besançon, Université de Franche-Comté ( UFC ) -Université de Franche-Comté ( UFC ), Centre Alexis Vautrin ( CAV ), Ecophysiologie Végétale, Agronomie et Nutritions ( EVA ), Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Recherche Agronomique ( INRA ), Image et ville ( IV ), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique ( CNRS ), Département informatique ( INFO ), Université européenne de Bretagne ( UEB ) -Télécom Bretagne-Institut Mines-Télécom [Paris], Service de Gastro-entérologie [Avicenne], Université Paris 13 ( UP13 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne, Agence de l'Environnement et de la Maîtrise de l'Energie - ADEME, Service d'hépato-gastroentérologie, CHU Caen-Hôpital côte de nacre, Département de Médecine, Centre hospitalier de Libourne, Service d'Hépato-Gastro-Entérologie (CHU de Dijon), Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Fondation FondaMental, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor, Variabilité de réponse aux psychotropes ( VariaPsy - U1144 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Diderot - Paris 7 ( UPD7 ), Département d'oncologie digestive, Institut Bergonié - CRLCC Bordeaux, Hôpital St Joseph, Service de Gynécologie et d'Obstétrique ( CHU Lyon ), Hospices Civils de Lyon ( HCL ), Gastro - Entérologie et Nutrition, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Génétique, Immunothérapie, Chimie et Cancer ( GICC ), Université de Tours-Centre National de la Recherche Scientifique ( CNRS ), Université Montpellier 1 ( UM1 ), Service de gastro-entérologie - Hôpital Henri Mondor, Laboratoire Matière et Systèmes Complexes ( Laboratoire MSC ), Université Paris Diderot - Paris 7 ( UPD7 ) -UFR de Physique, France, Amériques, Espagne – Sociétés, pouvoirs, acteurs ( FRAMESPA ), Université Toulouse - Jean Jaurès ( UT2J ) -Centre National de la Recherche Scientifique ( CNRS ), Regional Hospital of Orleans, Histoire, Archéologie et littératures des Mondes chrétiens et musulmans médiévaux ( CIHAM ), École normale supérieure - Lyon ( ENS Lyon ) -Université Lumière - Lyon 2 ( UL2 ) -École des hautes études en sciences sociales ( EHESS ) -Université Jean Moulin - Lyon III ( UJML ) -Université d'Avignon et des Pays de Vaucluse ( UAPV ) -Centre National de la Recherche Scientifique ( CNRS ), Neurobiologie des signaux intercellulaires ( NSI ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Centre National de la Recherche Scientifique ( CNRS ), Dept Med Genet, Hôpital Erasme (Bruxelles), Polyclinique de Limoges - site François Chénieux [Limoges], Clinique Médicale B, CHU Strasbourg, Service de gastro-entérologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz, Hôpital Européen [Fondation Ambroise Paré - Marseille], Asklepios Klinikum Uckermark GmbH, DESY, Notkestr 85, D-22607 Hamburg, Germany, NASA Ames Research Center ( ARC ), Department of Chemistry, Center for Structural Biology, Vanderbilt University [Nashville], Biostatistique et Processus Spatiaux ( BIOSP ), Institute of Ecology [Jena], Friedrich-Schiller-Universität Jena, University of Rostock [Germany], Universität Stuttgart [Stuttgart], Oneonta, Zentrum für Innere Medizin, Klinikum Schwäbisch Gmünd/Stauferklinik, Physiopathologie du stress pancréatique, Institut Armand Frappier ( INRS-IAF ), Institut National de la Recherche Scientifique [Québec] ( INRS ) -Réseau International des Instituts Pasteur ( RIIP ) -Institut Armand Frappier, Institut de Mathématiques de Marseille ( I2M ), Aix Marseille Université ( AMU ) -Ecole Centrale de Marseille ( ECM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre des Sciences du Goût et de l'Alimentation [Dijon] ( CSGA ), Institut National de la Recherche Agronomique ( INRA ) -Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Department of Computer Science [Freiburg], University of Freiburg [Freiburg], Institut für Mathematik [Berlin], Technische Universität Berlin ( TUB ), Department of Information Engineering, Computer Science and Mathematics, Università degli Studi dell'Aquila [L'Aquila] ( UNIVAQ.IT ), Department of Animal Sciences, North Carolina Agricultural and Technical State University, FEEM, Romagna Cancer Registry, IRST, Luigi Pierantoni Hospital, Observatoire sociologique du changement ( OSC ), Sciences Po-Centre National de la Recherche Scientifique ( CNRS ), Dipartimento di Chimica, Fisica e Ambiente, Università degli Studi di Udine - University of Udine [Italie], Department of Nuclear Medicine, PET/CT Centre, Centre de Psychiatrie et Neurosciences ( CPN - U894 ), Clinica di Oncologia Medica, AO Ospedali Riuniti, Università Politecnica delle Marche [Ancona] ( UNIVPM ), Universidade Nova de Lisboa ( UNINOVA ), Ottawa Hospital Research Institute [Ottawa] ( OHRI ), Oncologia Medica, Ospedali Riuniti, Ospedale 'San Vincenzo', NIPE, CIPES, European Synchrotron Radiation Facility ( ESRF ), Departamento de Engenharia Informática, Faculdade de Engenharia [Porto] ( FEUP ), Universidade do Porto [Porto]-Universidade do Porto [Porto], 3Decide, Unité de recherche Amélioration, Génétique et Physiologie Forestières ( UAGPF ), Universidade Federal de Campina Grande [Campina Grande] ( UFCG ), Instituto de Engenharia de Sistemas e Computadores ( INESC ), Departamento de Ciências Biológicas, Universidade Regional do Cariri ( URCA Brasil ), Department of Biochemistry and Molecular Biology [Barcelona, Spain], Universitat de Barcelona ( UB ), Associated Unit to Consejo Superior de Investigaciones Científicas - CSIC [Barcelona, Spain], University of Barcelona-Institute of Biomedicine - IBUB [Barcelona, Spain], IRCELYON-Caractérisation et remédiation des polluants dans l'air et l'eau ( CARE ), Institut de recherches sur la catalyse et l'environnement de Lyon ( IRCELYON ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'analyse et d'architecture des systèmes [Toulouse] ( LAAS ), Centre National de la Recherche Scientifique ( CNRS ) -Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse ( INSA Toulouse ), Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ) -Institut National Polytechnique [Toulouse] ( INP ), Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier ( ICGM ICMMM ), Université Montpellier 1 ( UM1 ) -Université Montpellier 2 - Sciences et Techniques ( UM2 ) -Ecole Nationale Supérieure de Chimie de Montpellier ( ENSCM ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Instituto de Ciencia de Materiales de Madrid [Madrid] ( ICMM ), Interactions, Corpus, Apprentissages, Représentations ( ICAR ), École normale supérieure - Lyon ( ENS Lyon ) -Université Lumière - Lyon 2 ( UL2 ) -INRP-Ecole Normale Supérieure Lettres et Sciences Humaines-Centre National de la Recherche Scientifique ( CNRS ), Institut d'Investigacions Biomèdiques August Pi i Sunyer ( IDIBAPS ), North Region Cancer Registry of Portugal, UMR 5805 Environnements et Paléoenvironnements Océaniques et Continentaux ( EPOC ), Observatoire aquitain des sciences de l'univers ( OASU ), Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers ( INSU - CNRS ) -Centre National de la Recherche Scientifique ( CNRS ) -École pratique des hautes études ( EPHE ) -Centre National de la Recherche Scientifique ( CNRS ), Department of Paediatrics and Intensive Care, Hospital Universitari Sant Joan de Deu, Laboratoire de Psychologie Sociale ( LPS ), Aix Marseille Université ( AMU ), Universitat de València ( UV ), Instituto de Cienca de Materiales de Madrid [Madrid] ( ICMM ), Biology, New Mexico State University, New Mexico State University, Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ), Centre de recherche sur les Ions, les MAtériaux et la Photonique ( CIMAP - UMR 6252 ), Centre National de la Recherche Scientifique ( CNRS ) -Ecole Nationale Supérieure d'Ingénieurs de Caen ( ENSICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ), Institut d'Electronique et de Télécommunications de Rennes ( IETR ), Université de Nantes ( UN ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National des Sciences Appliquées - Rennes ( INSA Rennes ) -CentraleSupélec-Centre National de la Recherche Scientifique ( CNRS ), Computer Science Department - Carnegie Mellon University, University of Pittsburgh, Laboratoire de Sciences Actuarielle et Financière ( SAF ), Université de Lyon-Université de Lyon, Instituto de Oncologia Corachan ( IDOC ), Laboratoire d'informatique de l'école normale supérieure ( LIENS ), École normale supérieure - Paris ( ENS Paris ) -Centre National de la Recherche Scientifique ( CNRS ), Experimental Quantum Optics and Photonics Group, University of Strathclyde, Institut de recherches Asiatiques ( IrAsia ), Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Européen de Réalité Virtuelle ( CERV ), École Nationale d'Ingénieurs de Brest ( ENIB ), Sol Agro et hydrosystème Spatialisation ( SAS ), Institut National de la Recherche Agronomique ( INRA ) -AGROCAMPUS OUEST, Grenoble Institut des Neurosciences ( GIN ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Grenoble-Université Joseph Fourier - Grenoble 1 ( UJF ), Centre de recherche cerveau et cognition ( CERCO ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Laboratoire Géomatériaux et Environnement ( LGE ), Université Paris-Est Marne-la-Vallée ( UPEM ), Hôpital Ambroise Paré [AP-HP], Université Paris-Saclay, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, Université de Nantes (UN), Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique (MEPPOT - U1147), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Salzburger Landesklinikum - Uniklinikum Salzburg (SALK), Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung (AWI), Institut des Sciences Moléculaires de Marseille (ISM2), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Institut de Chimie du CNRS (INC), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Institut de Biologie Computationnelle (IBC), Université de Montpellier (UM)-Institut National de la Recherche Agronomique (INRA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre National de la Recherche Scientifique (CNRS), Institut des Sciences Moléculaires (ISM), Université Montesquieu - Bordeaux 4-Université Sciences et Technologies - Bordeaux 1-École Nationale Supérieure de Chimie et de Physique de Bordeaux (ENSCPB)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Universiteit Gent = Ghent University [Belgium] (UGENT), Antwerp University Hospital [Edegem] (UZA), Hillerød Hospital, Copenhagen University Hospital-Copenhagen University Hospital, Centre Hospitalier Universitaire de Reims (CHU Reims), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université du Québec à Montréal = University of Québec in Montréal (UQAM), Université Paris 1 Panthéon-Sorbonne (UP1), École nationale supérieure d'architecture de Nantes (ENSA Nantes), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Unité de recherche sur les Biopolymères, Interactions Assemblages (BIA), Institut National de la Recherche Agronomique (INRA), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bretagne Occidentale - École de sages-femmes (UBO UFR MSS ESF), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Alexis Vautrin (CAV), Ecophysiologie Végétale, Agronomie et Nutritions (EVA), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Recherche Agronomique (INRA), Image et ville (IV), Université Louis Pasteur - Strasbourg I-Centre National de la Recherche Scientifique (CNRS), Département informatique (INFO), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Agence de l'Environnement et de la Maîtrise de l'Energie (ADEME), Service d'Hépato-Gastro-Enterologie et Nutrition [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Libourne, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Fondation FondaMental [Créteil], Variabilité de réponse aux Psychotropes (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Service de Gynécologie et d'Obstétrique (CHU Lyon), Hospices Civils de Lyon (HCL), Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS [2012-2017] (GICC UMR 7292 CNRS), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Université Montpellier 1 (UM1), Service de gastro-entérologie [Henri Mondor AP-HP, Créteil], Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Matière et Systèmes Complexes (MSC (UMR_7057)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Hôpital privé Toulon Hyères : Sainte Marguerite, Clinique des Quatre Pavillons, Lormont, France, Neurobiologie des signaux intercellulaires (NSI), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB)-Faculté de Médecine [Bruxelles] (ULB), NASA Ames Research Center (ARC), Biostatistique et Processus Spatiaux (BioSP), Friedrich-Schiller-Universität = Friedrich Schiller University Jena [Jena, Germany], University of Rostock, State University of New York at Oneonta (SUNY Oneonta), State University of New York (SUNY), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Armand Frappier (INRS-IAF), Réseau International des Instituts Pasteur (RIIP)-Institut National de la Recherche Scientifique [Québec] (INRS), Institut de Mathématiques de Marseille (I2M), Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS), Klinikum Deggendorf, Technische Universität Berlin (TU), Università degli Studi dell'Aquila (UNIVAQ), North Carolina A&T State University, University of North Carolina System (UNC)-University of North Carolina System (UNC), Observatoire sociologique du changement (OSC), Sciences Po (Sciences Po)-Centre National de la Recherche Scientifique (CNRS), Institut de psychiatrie et neurosciences (U894 / UMS 1266), Università Politecnica delle Marche [Ancona] (UNIVPM), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Ottawa Hospital Research Institute [Ottawa] (OHRI), European Synchrotron Radiation Facility (ESRF), Departamento de Engenharia Informática [Porto], Faculdade de Engenharia da Universidade do Porto (FEUP), Universidade do Porto-Universidade do Porto, Universidade Federal de Campina Grande [Campina Grande] (UFCG), Instituto de Engenharia de Sistemas e Computadores (INESC), Universidade Regional do Cariri (URCA Brasil), Universitat de Barcelona (UB), IRCELYON-Catalytic and Atmospheric Reactivity for the Environment (CARE), Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Laboratoire d'analyse et d'architecture des systèmes (LAAS), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées, Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier (ICGM ICMMM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut de Chimie du CNRS (INC), Instituto de Ciencia de Materiales de Madrid (ICMM), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Interactions, Corpus, Apprentissages, Représentations (ICAR), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-INRP-Ecole Normale Supérieure Lettres et Sciences Humaines (ENS LSH)-Centre National de la Recherche Scientifique (CNRS), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), UMR 5805 Environnements et Paléoenvironnements Océaniques et Continentaux (EPOC), Observatoire aquitain des sciences de l'univers (OASU), Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS), Hospital Universitario de Valme, Anenida de Bellavista s/n, Sevilla 41014, Spain, Hospital Son Llatzer, Universitat de València (UV), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hospital Universitari Son Espases, University of Pittsburgh (PITT), Pennsylvania Commonwealth System of Higher Education (PCSHE)-Pennsylvania Commonwealth System of Higher Education (PCSHE), Instituto de Oncologia Corachan (IDOC), Laboratoire d'informatique de l'école normale supérieure (LIENS), École normale supérieure - Paris (ENS Paris), Institut de recherches Asiatiques (IrAsia), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre Européen de Réalité Virtuelle (CERV), École Nationale d'Ingénieurs de Brest (ENIB), Sol Agro et hydrosystème Spatialisation (SAS), Institut National de la Recherche Agronomique (INRA)-AGROCAMPUS OUEST, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Grenoble Institut des Neurosciences (GIN), Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche cerveau et cognition (CERCO), Institut des sciences du cerveau de Toulouse. (ISCT), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Géomatériaux et Environnement (LGE), Université Paris-Est Marne-la-Vallée (UPEM), Fédération Francophone de Cancérologie Digestive (FFCD), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Recherche Agronomique (INRA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Service d'Oncologie Médicale [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut National de la Recherche Agronomique (INRA)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Institut National de la Recherche Scientifique [Québec] (INRS)-Réseau International des Instituts Pasteur (RIIP), Department of Information Engineering, Computer Science and Mathematics = Dipartimento di Ingegneria e Scienze dell'Informazione e Matematica [L'Aquila] (DISIM), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institut Charles Gerhardt Montpellier - Institut de Chimie Moléculaire et des Matériaux de Montpellier (ICGM), Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Département d'informatique - ENS Paris (DI-ENS), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de Recherche en Informatique et en Automatique (Inria)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-École Centrale de Marseille (ECM)-Aix Marseille Université (AMU), Institute of Biomedicine - IBUB [Barcelona, Spain]-University of Barcelona, Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), AGROCAMPUS OUEST, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de la Recherche Agronomique (INRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure de Chimie et de Physique de Bordeaux (ENSCPB)-Université Sciences et Technologies - Bordeaux 1-Université Montesquieu - Bordeaux 4-Institut de Chimie du CNRS (INC), AGROCAMPUS OUEST-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Physiologie Animale et Systèmes d'Elevage (PHASE), Institut National de la Recherche Agronomique (INRA)-Environnement et Agronomie (E.A.)-Biologie et Amélioration des Plantes (BAP)-Fourrages Environnement Ruminants Lusignan (FERLUS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré, University of Florence (UNIFI), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Imagerie Moléculaire et Stratégies Théranostiques - Clermont Auvergne (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Institut de cancérologie de l'Ouest - Nantes (ICO Nantes), Université Montesquieu - Bordeaux 4-Université Sciences et Technologies - Bordeaux 1-École Nationale Supérieure de Chimie et de Physique de Bordeaux (ENSCPB)-Centre National de la Recherche Scientifique (CNRS), Ghent University [Belgium] (UGENT), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université du Québec à Montréal (UQAM), Université Panthéon-Sorbonne (UP1), Centre hospitalier universitaire d'Amiens (CHU Amiens-Picardie), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Centre de Recherche Saint-Antoine (CR Saint-Antoine), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université de Franche-Comté (UFC)-Université de Franche-Comté (UFC), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris 13 (UP13)-Hôpital Avicenne, Optimisation Thérapeutique en Neuropsychopharmacologie (VariaPsy - U1144), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz, Biostatistique et Processus Spatiaux (BIOSP), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Technische Universität Berlin (TUB), Università degli Studi dell'Aquila [L'Aquila] (UNIVAQ.IT), Universidade Nova de Lisboa (NOVA), Faculdade de Engenharia [Porto] (FEUP), Unité de recherche Amélioration, Génétique et Physiologie Forestières (UAGPF), IRCELYON-Caractérisation et remédiation des polluants dans l'air et l'eau (CARE), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse 1 Capitole (UT1)-Université Toulouse - Jean Jaurès (UT2J), Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Consejo Superior de Investigaciones Científicas [Spain] (CSIC), École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-INRP-Ecole Normale Supérieure Lettres et Sciences Humaines-Centre National de la Recherche Scientifique (CNRS), Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Sciences et Technologies - Bordeaux 1-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-École pratique des hautes études (EPHE)-Centre National de la Recherche Scientifique (CNRS), École normale supérieure - Paris (ENS Paris)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut des sciences du cerveau de Toulouse. (ISCT), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Institut National de la Santé et de la Recherche Médicale (INSERM), Emile, J, Julie, C, Le Malicot, K, Lepage, C, Tabernero, J, Mini, E, Folprecht, G, Van Laethem, J, Dimet, S, Boulagnon-Rombi, C, Allard, M, Penault-Llorca, F, Bennouna, J, Laurent-Puig, P, Taieb, J, Bidoli, P, Emile, J. -F., Julie, C., Le Malicot, K., Lepage, C., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. -L., Dimet, S., Boulagnon-Rombi, C., Allard, M. -A., Penault-Llorca, F., Bennouna, J., Laurent-Puig, P., Taieb, J., Thaler, J., Greil, R., Gaenzer, J., Eisterer, W., Tschmelitsch, J., Keil, F., Samonigg, H., Zabernigg, A., Schmid, F., Steger, G., Steinacher, R., Andel, J., Jagdt, B., Lang, A., Fridrik, M., Fugger, R., Hofbauer, F., Woell, E., Geissler, D., Lenauer, A., Prager, M., D'Haens, G., Demolin, G., Kerger, J., Deboever, G., Ghillebert, G., Polus, M., Van Cutsem, E., Kalantari, H. R., Delaunoit, T., Goeminne, J. C., Peeters, M., Vergauwe, P., Houbiers, G., Humblet, Y., Janssens, J., Schrijvers, D., Vanderstraeten, E., Vermorken, J., Van Daele, D., Ferrante, M., Forget, F., Hendlisz, A., Yilmaz, M., Nielsen, S. E., Vestermark, L., Larsen, J., Zawadi, M. -A., Bouche, O., Mineur, L., Bennouna-Louridi, J., Dourthe, L. M., Ychou, M., Boucher, E., Pezet, D., Desseigne, F., Ducreux, M., Texereau, P., Miglianico, L., Rougier, P., Fratte, S., Levache, C. -B., Merrouche, Y., Ellis, S., Locher, C., Ramee, J. -F., Garnier, C., Viret, F., Chauffert, B., Cojean-Zelek, I., Michel, P., Lecaille, C., Borel, C., Seitz, J. -F., Smith, D., Lombard-Bohas, C., Andre, T., Gornet, J. -M., Fein, F., Coulon-Sfairi, M. -A., Kaminsky, M. -C., Lagasse, J. -P., Luet, D., Etienne, P. -L., Gasmi, M., Vanoli, A., Nguyen, S., Aparicio, T., Perrier, H., Stremsdoerfer, N., Laplaige, P., Arsene, D., Auby, D., Bedenne, L., Coriat, R., Denis, B., Geoffroy, P., Piot, G., Becouarn, Y., Bordes, G., Deplanque, G., Dupuis, O., Fruge, F., Guimbaud, R., Lecomte, T., Lledo, G., Sobhani, I., Asnacios, A., Azzedine, A., Desauw, C., Galais, M. -P., Gargot, D., Lam, Y. -H., Abakar-Mahamat, A., Berdah, J. -F., Catteau, S., Clavero-Fabri, M. -C., Codoul, J. -F., Legoux, J. -L., Goldfain, D., Guichard, P., Verge, D. P., Provencal, J., Vedrenne, B., Brezault-Bonnet, C., Cleau, D., Desir, J. -P., Fallik, D., Garcia, B., Gaspard, M. -H., Genet, D., Hartwig, J., Krummel, Y., Budnik, T. M., Palascak-Juif, V., Randrianarivelo, H., Rinaldi, Y., Aleba, A., Darut-Jouve, A., de Gramont, A., Hamon, H., Wendehenne, F., Matzdorff, A., Stahl, M. K., Schepp, W., Burk, M., Mueller, L., Geissler, M., Mantovani-Loeffler, L., Hoehler, T., Asperger, W., Kroening, H., von Weikersthal, L. F., Fuxius, S., Groschek, M., Meiler, J., Trarbach, T., Rauh, J., Ziegenhagen, N., Kretzschmar, A., Graeven, U., Nusch, A., von Wichert, G., Hofheinz, R. -D., Kleber, G., Schmidt, K. -H., Vehling-Kaiser, U., Baum, C., Schuette, J., Haag, G. M., Holtkamp, W., Potenberg, J., Reiber, T., Schliesser, G., Schmoll, H. -J., Schneider-Kappus, W., Abenhardt, W., Denzlinger, C., Henning, J., Marxsen, B., Derigs, H. G., Lambertz, H., Becker-Boost, I., Caca, K., Constantin, C., Decker, T., Eschenburg, H., Gabius, S., Hebart, H., Hoffmeister, A., Horst, H. -A., Kremers, S., Leithaeuser, M., Mueller, S., Wagner, S., Daum, S., Schlegel, F., Stauch, M., Heinemann, V., Maiello, E., Latini, L., Zaniboni, A., Amadori, D., Aprile, G., Barni, S., Mattioli, R., Martoni, A., Passalacqua, R., Nicolini, M., Pasquini, E., Rabbi, C., Aitini, E., Ravaioli, A., Barone, C., Biasco, G., Tamberi, S., Gambi, A., Verusio, C., Marzola, M., Lelli, G., Boni, C., Cascinu, S., Bidoli, P., Vaghi, M., Cruciani, G., Di Costanzo, F., Sobrero, A., Petrioli, R., Aglietta, M., Alabiso, O., Capuzzo, F., Falcone, A., Corsi, D. C., Labianca, R., Salvagni, S., Chiara, S., Ciuffreda, L., Ferrau, F., Giuliani, F., Lonardi, S., Gebbia, N., Mantovani, G., Sanches, E., Mellidez, J. C., Santos, P., Freire, J., Sarmento, C., Costa, L., Pinto, A. M., Barroso, S., Santo, J. E., Guedes, F., Monteiro, A., Sa, A., Furtado, I., Salazar, R., Aguilar, E. A., Herrero, F. R., Valera, J. S., Ayerbes, M. V., Batlle, J. F., Gil, S., Esteve, A. A., Garcia-Giron, C., Vivanco, G. L., Salvia, A. S., Orduna, V. A., Garcia, R. V., Gallego, J., Sureda, B. M., Remon, J., Safont Aguilera, M. J., Nogueras, L. C., Merino, B. Q., Castro, C. G., de Prado, P. M., Pericay, C. P., Figueiras, M. C., Jordan, I. G., Gome Reina, M. J., Garcia, A. L. -L., Garcia-Ramos, A. A., Cervantes, A., Martos, C. F., Gaspar, E. M., Montero, I. C., Emperador, P. E., Carbonero, A. L., Castillo, M. G., Garcia, T. G., Lopez, J. G., Flores, E. G., Morales, M. G., Munoz, M. L., Martin, A. L., Maurel, J., Camara, J. C., Garcia, R. D., Salgado, M., Busquier, I. H., Ruiz, T. C., Munoa, A. L., Aliguer, M. N., de Taranco, A. V. O., Urena, M. M., Gaspa, F. L., Ponce, J. J., Roig, C. B., Jimenez, P. V., Brotons, A. G., Rodriguez, S. A., Martinez, J. A., Ruiz, L. C., Ruiz, M. C., Bridgewater, J., Glynne-Jones, R., Tahir, S., Hickish, T., Cassidy, J., and Samuel, L.

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Organoplatinum Compounds, Colorectal cancer, medicine.medical_treatment, Medizin, Leucovorin, Prospective cohort study, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, FOLFOX, Organoplatinum Compounds/therapeutic use, Antineoplastic Combined Chemotherapy Protocols, tudy, Lymphocytes, Prospective Studies, Leucovorin/therapeutic use, Middle Aged, Prognosis, 3. Good health, Colorectal carcinoma, Fluorouracil, 030220 oncology & carcinogenesis, Predictive value of tests, Colonic Neoplasms, Biomarker (medicine), Lymphocytes/pathology, Female, Adjuvant, medicine.drug, Adult, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, Fluorouracil/therapeutic use, Biomarkers, Tumor/analysis, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, Predictive Value of Tests, Biomarker, Immune response, Internal medicine, medicine, Biomarkers, Tumor, Humans, Survival analysis, Aged, business.industry, medicine.disease, Survival Analysis, Surgery, 030104 developmental biology, Prospective cohort&nbsp, Multivariate Analysis, Colonic Neoplasms/diagnosis, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, business
Abstract

IF 6.029; International audience; BackgroundThe prognostic value of lymphocyte infiltration (LI) of colorectal carcinoma (CC) has been demonstrated by several groups. However, no validated test is currently available for clinical practice. We previously described an automated and reproducible method for testing LI and aimed to validate it for clinical use.Patients and methodsAccording to National Institutes of Health criteria, we designed a prospective validation of this biomarker in patients included in the PETACC8 phase III study. Primary objective was to compare percentage of patients alive and without recurrence at 2 years in patients with high versus low LI (#NCT02364024). Associations of LI with patient recurrence and survival were analysed, and multivariable models were adjusted for treatment and relevant factors. Automated testing of LI was performed on virtual slides without access to clinical data.ResultsAmong the 1220 CC patients enrolled, LI was high, low and not evaluable in 241 (19.8%), 790 (64.8%) and 189 (15.5%), respectively. Primary objective was met with a 2-year recurrence rate of 14.4% versus 21.1% in patients with high and low LI, respectively (p = 0.02). Patients with high LI also had better disease free survival (DFS) and overall survival (OS). Tumour stage, grade, RAS status and BRAF status were with LI the only prognostic markers in multivariable analysis for OS. Subgroup analyses revealed that high LI had better DFS and OS in mismatch repair (MMR) proficient patients, and in patients without RAS mutation, but not in MMR deficient and RAS mutated patients.ConclusionAlthough this is the first validation with high level of evidence (IIB) of the prognostic value of a LI test in colon cancers, it still needs to be confirmed in independent series of colon cancer patients.

Published
2017

10. Results of short term radiotherapy followed by radical surgery for rectal cancer: A long-term unicenter observational study

Author

Mikel Osorio, José María Enríquez-Navascués, Maddi Garmendia, Adelaida Lacasta, Juan Pablo Ciria, Yolanda Saralegui, Garazi Elorza, and Carlos Placer

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, Colorectal cancer, medicine.medical_treatment, 030230 surgery, Anastomosis, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Epidemiology, Preoperative Care, medicine, Humans, Longitudinal Studies, Radical surgery, Pathological, Chronic toxicity, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Rectal Neoplasms, Incidence (epidemiology), General Engineering, Middle Aged, medicine.disease, Combined Modality Therapy, Surgery, Radiation therapy, 030220 oncology & carcinogenesis, Female, business
Abstract

Introduction Short-term radiotherapy (STR) for rectal cancer (RC) has rarely been used in Spain. The aim of the present study is to describe oncological results after RTC and surgery for RC. Methods This is a retrospective analysis of a consecutive series of patients treated with STR and surgery for RC (1999–2012). Epidemiological data, staging, complications of STR, STR-surgery interval, surgical approach, rate of anastomotic/perineal wound dehiscence, and pathological data (regression degree and staging) were collected. Global survival, disease free survival, local recurrence rate and incidence of toxicity, response and complications of combined treatment are reported. Results Of 1229 patients treated, 209 patients received STR and surgery. The median follow-up was 6.2 years. Mean age was 68 years and 66% of the patients were men. A total of 88% were cT3-4 and 44% cN+17 (8.1%) patients had resectable synchronous metastases. Acute and chronic toxicity due to STR was 4 weeks. Seven patients (3.3%) presented complete response. Nine (4.3%) patients presented a local recurrence rate. Global survival at 5, 10 and 15 years was 67.8%, 49.2% and 37.5%, respectively. Disease free survival at 5, 10 and 15 years was 66.1%, 47.1% and 33%, respectively. Conclusions The results compare favorably with multicentric historical series. STR offers certain advantages that could be increased by increasing the STR-surgery interval and/or interspersed with sequential chemotherapy.

Published
2017

11. Usefulness of serum metabolic profiling in the search of novel diagnostic biomarkers for primary sclerosing cholangitis, intrahepatic cholangiocarcinoma and hepatocellular carcinoma

Author

Jordi Muntané, Luis González, Luis Muñoz-Bellvís, Adelaida Lacasta, Jose J.G. Marin, Bruno Sangro, Ander Arbelaiz, Piotr Milkiewicz, R.I.R. Macias, Enara Arretxe, Cristina Alonso, Jesus M. Banales, Mercedes Iñarrairaegui, and Luis Bujanda

Subjects
Pathology, medicine.medical_specialty, Hepatology, business.industry, medicine.disease, Primary sclerosing cholangitis, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, medicine, Diagnostic biomarker, 030211 gastroenterology & hepatology, business, Intrahepatic Cholangiocarcinoma
Published
2018

12. Outcomes of open versus laparoscopic surgery in patients with colon cancer

Author

Quintana, José M., primary, Antón-Ladisla, Ane, additional, González, Nerea, additional, Lázaro, Santiago, additional, Baré, Marisa, additional, Fernández de Larrea, Nerea, additional, Redondo, Maximino, additional, Briones, Eduardo, additional, Escobar, Antonio, additional, Sarasqueta, Cristina, additional, García-Gutierrez, Susana, additional, Quintana López, Jose María, additional, Mañas, Marisa Baré, additional, Bautista, Maximino Redondo, additional, Pérez de la Blanca, Eduardo Briones, additional, Fernández de Larrea Baz, Nerea, additional, Eizaguirre, Cristina Sarasqueta, additional, Martínez, Antonio Escobar, additional, Ruiz, Francisco Rivas, additional, Morales-Suárez-Varela, Maria M., additional, Blasco Amaro, Juan Antonio, additional, González, Isabel del Cura, additional, Madariaga, Inmaculada Arostegui, additional, González, Amaia Bilbao, additional, Hernández, Nerea González, additional, García-Gutiérrez, Susana, additional, Guerrero, Iratxe Lafuente, additional, Larracoechea, Urko Aguirre, additional, Calzada, Miren Orive, additional, Corral, Josune Martin, additional, Antón-Ladislao, Ane, additional, Torà, Núria, additional, Pont, Marina, additional, Martínez del Prado, María Purificación, additional, Totorikaguena, Alberto Loizate, additional, Estévez, Ignacio Zabalza, additional, Alustiza, José Errasti, additional, Gimeno García, Antonio Z., additional, Aramburu, Santiago Lázaro, additional, Serrano, Mercè Comas, additional, Enríquez Navascues, Jose María, additional, Galán, Carlos Placer, additional, Perales, Amaia, additional, Valmaña, Iñaki Urkidi, additional, Erro Azkárate, Jose María, additional, Lizarribar, Enrique Cormenzana, additional, Muñoa, Adelaida Lacasta, additional, Pibernat, Pep Piera, additional, Cuevas, Elena Campano, additional, Sotelo Gómez, Ana Isabel, additional, Gómez-Abril, Segundo, additional, Medina-Cano, F., additional, Alcaide, Julia, additional, Del Rey-Moreno, Arturo, additional, Alcántara, Manuel Jesús, additional, Campo, Rafael, additional, Casalots, Alex, additional, Pericay, Carles, additional, Gil, Maria José, additional, Pera, Miquel, additional, Collera, Pablo, additional, Espinàs, Josep Alfons, additional, Martínez, Mercedes, additional, Espallargues, Mireia, additional, Almazán, Caridad, additional, Lindenbaum, Paula Dujovne, additional, Fernández-Cebrián, José María, additional, Fernández, Rocío Anula, additional, Mayol Martínez, Julio Ángel, additional, Cid, Ramón Cantero, additional, Labajo, Héctor Guadalajara, additional, Garceau, María Heras, additional, Olmo, Damián García, additional, Montalvo, Mariel Morey, additional, and Mar, Javier, additional

Published
2018
Full Text
View/download PDF

14. Arbelaiz et al

Author

Tushar Patel, Adelaida Lacasta, J.P. Jimeno, Esperanza Gonzalez, Gregory J. Gores, Ainhoa Lapitz, Ander Arbelaiz, Frank Lammert, Marco Marzioni, Piotr Milkiewicz, Alvaro Santos-Laso, Mikel Azkargorta, A. Sanchez-Campos, C. Ibarra, Marcin Krawczyk, Jose J.G. Marin, Rocio I.R. Macias, Oihane Erice, Ibon Martinez, Luis Bujanda, Raul Jimenez-Agüero, Felix Elortza, Jesus M. Banales, Maria J. Perugorria, and Juan M. Falcón-Pérez

Subjects
0301 basic medicine, medicine.medical_specialty, Pathology, Proteome, Cholangitis, Sclerosing, Nanoparticle tracking analysis, Biology, Primary sclerosing cholangitis, Cholangiocarcinoma, 03 medical and health sciences, Extracellular Vesicles, Mice, 0302 clinical medicine, Internal medicine, Cell Line, Tumor, parasitic diseases, medicine, Animals, Humans, Hepatology, Cluster of differentiation, medicine.disease, digestive system diseases, Microvesicles, In vitro, 030104 developmental biology, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Case-Control Studies, Biomarkers
Abstract

Cholangiocarcinoma (CCA) includes a heterogeneous group of biliary cancers with poor prognosis. Several conditions, such as primary sclerosing cholangitis (PSC), are risk factors. Noninvasive differential diagnosis between intrahepatic CCA and hepatocellular carcinoma (HCC) is sometimes difficult. Accurate noninvasive biomarkers for PSC, CCA, and HCC are not available. In the search for novel biomarkers, serum extracellular vesicles (EV) were isolated from CCA (n = 43), PSC (n = 30), or HCC (n = 29) patients and healthy individuals (control, n = 32); and their protein content was characterized. By using nanoparticle tracking analysis, serum EV concentration was found to be higher in HCC than in all the other groups. Round morphology (by transmission electron microscopy), size (∼180 nm diameter by nanoparticle tracking analysis), and markers (clusters of differentiation 9, 63, and 81 by immunoblot) indicated that most serum EV were exosomes. Proteome profiles (by mass spectrometry) revealed multiple differentially expressed proteins among groups. Several of these proteins showed high diagnostic values with maximum area under the receiver operating characteristic curve of 0.878 for CCA versus control, 0.905 for CCA stage I-II versus control, 0.789 for PSC versus control, 0.806 for noncirhottic PSC versus control, 0.796 for CCA versus PSC, 0.956 for CCA stage I-II versus PSC, 0.904 for HCC versus control, and 0.894 for intrahepatic CCA versus HCC. Proteomic analysis of EV derived from CCA human cells in vitro revealed higher abundance of oncogenic proteins compared to EV released by normal human cholangiocytes. Orthotopic implant of CCA human cells in the liver of immunodeficient mice resulted in the release to serum of EV containing some similar human oncogenic proteins. Conclusion: Proteomic signatures found in serum EV of CCA, PSC, and HCC patients show potential usefulness as diagnostic tools. (Hepatology 2017;66:1125-1143).

Published
2016

15. Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen

Author

Rafael López, Margarita Reboredo, Elena Sánchez-Viñes, Begoña Pérez, Pilar Regueiro, Jorge Aparicio, R. Dueñas, B. Llorente, Carlos Gomez-Martin, R. Serrano, Antonio García Sánchez, Marta Llanos Muñoz, E. Falcó, Mª José Safont, Adelaida Lacasta, and Antonio Irigoyen

Subjects
Adult, Male, Oncology, Cancer Research, medicine.medical_specialty, Organoplatinum Compounds, medicine.medical_treatment, Deoxycytidine, Capecitabine, Stomach Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Neoplasm Metastasis, Aged, Epirubicin, Chemotherapy, integumentary system, business.industry, Incidence, Incidence (epidemiology), General Medicine, Middle Aged, Hand-Foot Syndrome, Oxaliplatin, Clinical trial, Regimen, Treatment Outcome, Fluorouracil, Female, Cisplatin, business, medicine.drug
Abstract

Hand-foot syndrome (HFS) is a limiting toxicity of capecitabine, which is not life-threatening but could compromise capecitabine efficacy.This phase II, multicenter, non-controlled study assessed the safety, particularly grade three HFS incidence, and efficacy of four capecitabine-based chemotherapy regimens [cisplatin/capecitabine (CX), epirubicin/cisplatin/capecitabine (ECX), epirubicin/oxaliplatin/capecitabine (EOX) and docetaxel/cisplatin/capecitabine (DCX)] as first-line treatment for advanced and/or metastatic gastric cancer.One hundred and eight patients were assigned to one of the four treatment groups, according to investigator's criteria, and grouped together for both safety and efficacy primary analyses. HFS was reported in 31 patients (19.6%) and its first presentation occurred at a median of 72 days (range 19-209 days). Grade 3 HFS developed in 6.3, 5.2, 3.7 and 2.4%, of patients receiving ECX, DCX, EOX or CX chemotherapy regimen, respectively. Capecitabine dose reduction/discontinuation due to HFS was required in 5.7% of patients (9/158). The most common (10%) grade 3-4 treatment-related AEs were neutropenia (15.2%), asthenia (12.0%) and diarrhoea (11.4%).A moderate incidence of HFS was reported in patients treated with capecitabine, which generally presented late and required dose reduction in1/3 of patients. The results suggest that capecitabine may be useful in combination with standard fluorouracil-based regimens in patients with advanced and/or metastatic gastric cancer with favourable safety profile.

Published
2012

16. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

Author

Juan M. Falcón-Pérez, Tushar Patel, Ander Arbelaiz, Gregory J. Gores, Alvaro Santos-Laso, Mikel Azkargorta, J.P. Jimeno, Marco Marzioni, Paula Olaizola, Ibon Martinez, P.Y. Lee, Luis Bujanda, M.J. Perugorria, Esperanza Gonzalez, Adelaida Lacasta, A. Arregi, Rocio I.R. Macias, Jose J.G. Marin, A. Sanchez-Campos, C. Ibarra, L. Izquierdo, Marek Krawczyk, Frank Lammert, O. Erice, Ainhoa Lapitz, Raul Jimenez-Agüero, Felix Elortza, and Jesus M. Banales

Subjects
0301 basic medicine, Pathology, medicine.medical_specialty, Hepatology, Protein biomarkers, Chemistry, medicine.disease, Extracellular vesicles, Primary sclerosing cholangitis, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine, 030211 gastroenterology & hepatology
Published
2017

17. Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain

Author

Antoni Arrivi, Pilar García-Alfonso, Jose Luis Manzano, M. Salgado, Eduardo Díaz-Rubio, Ruth Afonso, Auxiliadora Gómez-España, Cristina Grávalos, Adelaida Lacasta, Javier Sastre, Juan Carlos Cámara, Virginia Arrazubi, and Jaume Capdevila

Subjects
Cancer Research, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Rectum, Capecitabine, medicine, Humans, Expert Testimony, Digestive System Surgical Procedures, Neoadjuvant therapy, Chemotherapy, Rectal Neoplasms, business.industry, General surgery, General Medicine, Perioperative, medicine.disease, Combined Modality Therapy, Total mesorectal excision, Neoadjuvant Therapy, Surgery, Radiation therapy, medicine.anatomical_structure, Oncology, Practice Guidelines as Topic, business, medicine.drug
Abstract

In Spain 22,000 new cases of colorectal cancer are diagnosed each year, with 13,075 deaths resulting from this disease. Around 70% of colorectal cancers are localised in the colon and 30% in the rectum. A group of Spanish experts established recommendations on what would be the best strategy in the treatment of locally advanced rectal cancer (LARC). Adequate assessment of local tumour extension, including high-resolution magnetic resonance imaging and endorectal ultrasound, is essential for successful treatment. The three cornerstones in the treatment of LARC are surgery, radiotherapy and chemotherapy. Most patients will need a total mesorectal excision (TME). Preoperative chemo-radiotherapy (CRT) is preferred for the majority of patients with T3/T4 disease and/or regional node involvement, and adjuvant chemotherapy is recommended after a patient-sharing decision. Capecitabine, after showing a trend in improved downstaging in neoadjuvant stratum and the convenience of its oral administration, represents an alternative to 5-FU as perioperative treatment of LARC.

Published
2011

18. Novel protein biomarkers in serum extracellular vesicles for the diagnosis of primary sclerosing cholangitis (PSC) in patients with ulcerative colitis (UC)

Author

Frank Lammert, M.J. Perugorria, Piotr Milkiewicz, María Chaparro, Javier P. Gisbert, Tom H. Karlsen, C. Ibarra, Marek Krawczyk, Ainhoa Lapitz, Ander Arbelaiz, Esperanza Gonzalez, Jose J.G. Marin, Marco Marzioni, A. Sanchez-Campos, Felix Elortza, Jesus M. Banales, Luis Bujanda, Raul Jimenez-Agüero, Juan M. Falcón-Pérez, Alvaro Santos-Laso, Mikel Azkargorta, and Adelaida Lacasta

Subjects
medicine.medical_specialty, Hepatology, business.industry, Novel protein, Internal medicine, medicine, In patient, medicine.disease, business, Gastroenterology, Ulcerative colitis, Extracellular vesicles, Primary sclerosing cholangitis
Published
2018

19. Serum and urine extracellular vesicles contain mRNA biomarkers for primary sclerosing cholangitis (PSC) and cholangiocarcinoma (CCA)

Author

Luis Bujanda, Marco Marzioni, Juan M. Falcón-Pérez, A. Sanchez-Campos, Tom H. Karlsen, Ander Arbelaiz, Jose J.G. Marin, Alvaro Santos-Laso, Ainhoa Lapitz, Raul Jimenez-Agüero, J.P. Jimeno, Adelaida Lacasta, A. María Aransay, José Luis Lavín, Jesus M. Banales, Frank Lammert, R.I.R. Macias, M.J. Perugorria, Esperanza Gonzalez, C. Ibarra, and Marek Krawczyk

Subjects
0301 basic medicine, Messenger RNA, Pathology, medicine.medical_specialty, Hepatology, Chemistry, Urine, medicine.disease, Extracellular vesicles, Primary sclerosing cholangitis, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine, 030211 gastroenterology & hepatology
Published
2018

20. Características clinicopatológicas y supervivencia de los pacientes con cáncer de esófago. Resultados de 200 casos consecutivos

Author

Sara Arevalo, Luis Bujanda, Adelaida Lacasta, E. Hijona, Inés Gil, José Luis Elorza, José Ignacio Asensio, Julián Mínguez, Cristina Sarasqueta, Angel Cosme, and Santiago Larburu

Subjects
Gynecology, medicine.medical_specialty, business.industry, medicine, General Medicine, business
Abstract

Resumen Fundamento y objetivo El cancer de esofago (CE) es una enfermedad poco frecuente pero grave. El objetivo del presente trabajo es describir las caracteristicas clinicopatologicas y la supervivencia de los pacientes con CE en nuestro hospital. Pacientes y metodo Se estudio a 200 pacientes consecutivos diagnosticados o tratados de CE o de la union gastroesofagica en el Hospital Donostia entre enero del ano 2003 y diciembre del ano 2007. Se analizo la localizacion del tumor, el tipo histologico, las pruebas realizadas para establecer el estadio tumoral, los tratamientos utilizados, la supervivencia y la morbimortalidad de la cirugia. Resultados La ultrasonografia endoscopica (USE) modifico la estrategia terapeutica en un 12% de los pacientes. Un 32% (74) de los pacientes se operaron; de estos, un 65% (48) recibio radioquimioterapia (RT-QM) neoadyuvante. La supervivencia al ano, a los 3 anos y a los 5 anos fue del 48, el 25 y el 21%, respectivamente. La mortalidad postoperatoria fue del 8% (6 pacientes) y la morbilidad, del 57% (42 pacientes). Los pacientes en estadio III a los que se realizo RT-QM neoadyuvante y cirugia tuvieron un mejor pronostico que aquellos a los que solo se hizo RT-QM (20 meses de supervivencia frente a 9 meses). En el analisis multivariante, los factores de mal pronostico fueron la localizacion en el tercio medio (HR [hazard ratio ‘razon de riesgo’]=2,3; intervalo de confianza [IC] del 95%: 1,3–4,1) y la no realizacion de cirugia tras la RT-QM (HR=1,9; IC del 95%: 1,15–3). Conclusiones La USE mejoro la estrategia terapeutica en nuestros pacientes. La RT-QM neoadyuvante seguida de cirugia aumento la supervivencia en los estadios avanzados sin metastasis a distancia.

Published
2009

21. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

Author

Emile, Jean-François, primary, Julié, Catherine, additional, Le Malicot, Karine, additional, Lepage, Come, additional, Tabernero, Josep, additional, Mini, Enrico, additional, Folprecht, Gunnar, additional, Van Laethem, Jean-Luc, additional, Dimet, Stéphanie, additional, Boulagnon-Rombi, Camille, additional, Allard, Marc-Antoine, additional, Penault-Llorca, Frédérique, additional, Bennouna, Jaafar, additional, Laurent-Puig, Pierre, additional, Taieb, Julien, additional, Thaler, Josef, additional, Greil, Richard, additional, Gaenzer, Johannes, additional, Eisterer, Wolfgang, additional, Tschmelitsch, Joerg, additional, Keil, Felix, additional, Samonigg, Hellmut, additional, Zabernigg, August, additional, Schmid, Franz, additional, Steger, Günther, additional, Steinacher, Robert, additional, Andel, Johannes, additional, Jagdt, Björn, additional, Lang, Alois, additional, Fridrik, Michael, additional, Függer, Reinhold, additional, Hofbauer, Friedrich, additional, Woell, Ewald, additional, Geissler, Dietmar, additional, Lenauer, Alfred, additional, Prager, Manfred, additional, D'Haens, Geert, additional, Demolin, Gauthier, additional, Kerger, Joseph, additional, Deboever, Guido, additional, Ghillebert, Gilbert, additional, Polus, Marc, additional, Van Cutsem, Eric, additional, Kalantari, Hassan Rezaie, additional, Delaunoit, Thierry, additional, Goeminne, Jean Charles, additional, Peeters, Marc, additional, Vergauwe, Philippe, additional, Houbiers, Ghislain, additional, Humblet, Yves, additional, Janssens, Jos, additional, Schrijvers, Dirk, additional, Vanderstraeten, Erik, additional, Vermorken, Jan, additional, Van Daele, Daniel, additional, Ferrante, Michel, additional, Forget, Frederic, additional, Hendlisz, Alain, additional, Yilmaz, Mette, additional, Nielsen, Svend Erik, additional, Vestermark, Lene, additional, Larsen, Jim, additional, Zawadi, Mohamed-Ayman, additional, Bouche, Olivier, additional, Mineur, Laurent, additional, Bennouna-Louridi, Jaafar, additional, Dourthe, Louis Marie, additional, Ychou, Marc, additional, Boucher, Eveline, additional, Pezet, Denis, additional, Desseigne, Francoise, additional, Ducreux, Michel, additional, Texereau, Patrick, additional, Miglianico, Laurent, additional, Rougier, Philippe, additional, Fratte, Serge, additional, Levache, Charles-Briac, additional, Merrouche, Yacine, additional, Ellis, Stephen, additional, Locher, Christophe, additional, Ramee, Jean-Francois, additional, Garnier, Claire, additional, Viret, Frederic, additional, Chauffert, Bruno, additional, Cojean-Zelek, Isabelle, additional, Michel, Pierre, additional, Lecaille, Cedric, additional, Borel, Christian, additional, Seitz, Jean-Francois, additional, Smith, Denis, additional, Lombard-Bohas, Catherine, additional, Andre, Thierry, additional, Gornet, Jean-Marc, additional, Fein, Francine, additional, Coulon-Sfairi, Marie-Aude, additional, Kaminsky, Marie-Christine, additional, Lagasse, Jean-Paul, additional, Luet, Dominique, additional, Etienne, Pierre-Luc, additional, Gasmi, Mohamed, additional, Vanoli, Andre, additional, Nguyen, Suzanne, additional, Aparicio, Thomas, additional, Perrier, Hervé, additional, Stremsdoerfer, Noel, additional, Laplaige, Philippe, additional, Arsene, Dominique, additional, Auby, Dominique, additional, Bedenne, Laurent, additional, Coriat, Romain, additional, Denis, Bernard, additional, Geoffroy, Patrick, additional, Piot, Gilles, additional, Becouarn, Yves, additional, Bordes, Gilbert, additional, Deplanque, Gael, additional, Dupuis, Olivier, additional, Fruge, Frederic, additional, Guimbaud, Rosine, additional, Lecomte, Thierry, additional, Lledo, Gérard, additional, Sobhani, Iradej, additional, Asnacios, Amani, additional, Azzedine, Ahmed, additional, Desauw, Christophe, additional, Galais, Marie-Pierre, additional, Gargot, Dany, additional, Lam, You-Heng, additional, Abakar-Mahamat, Abakar, additional, Berdah, Jean-Francois, additional, Catteau, Sylviane, additional, Clavero-Fabri, Marie-Christine, additional, Codoul, Jean-Francois, additional, Legoux, Jean-Louis, additional, Goldfain, Denis, additional, Guichard, Pierre, additional, Verge, Denis Pere, additional, Provencal, Jocelyne, additional, Vedrenne, Bruno, additional, Brezault-Bonnet, Catherine, additional, Cleau, Denis, additional, Desir, Jean-Paul, additional, Fallik, David, additional, Garcia, Bruno, additional, Gaspard, Marie-Hélène, additional, Genet, Dominique, additional, Hartwig, Johannes, additional, Krummel, Yves, additional, Budnik, Tamara Matysiak, additional, Palascak-Juif, Vanessa, additional, Randrianarivelo, Harizo, additional, Rinaldi, Yves, additional, Aleba, Albert, additional, Darut-Jouve, Ariane, additional, de Gramont, Aimery, additional, Hamon, Herve, additional, Wendehenne, Frederic, additional, Matzdorff, Axel, additional, Stahl, Michael Konrad, additional, Schepp, Wolfgang, additional, Burk, Martin, additional, Mueller, Lothar, additional, Geissler, Michael, additional, Mantovani-Loeffler, Luisa, additional, Hoehler, Thomas, additional, Asperger, Walter, additional, Kroening, Hendrik, additional, von Weikersthal, Ludwig Fischer, additional, Fuxius, Stefan, additional, Groschek, Matthias, additional, Meiler, Johannes, additional, Trarbach, Tanja, additional, Rauh, Jacqueline, additional, Ziegenhagen, Nicolas, additional, Kretzschmar, Albrecht, additional, Graeven, Ullrich, additional, Nusch, Arnd, additional, von Wichert, Goetz, additional, Hofheinz, Ralf-Dieter, additional, Kleber, Gerhard, additional, Schmidt, Karl-Heinz, additional, Vehling-Kaiser, Ursula, additional, Baum, Claudia, additional, Schuette, Jochen, additional, Haag, Georg Martin, additional, Holtkamp, Wilhelm, additional, Potenberg, Jochen, additional, Reiber, Tobias, additional, Schliesser, Georg, additional, Schmoll, Hans-Joachim, additional, Schneider-Kappus, Wolfgang, additional, Abenhardt, Wolfgang, additional, Denzlinger, Claudio, additional, Henning, Jan, additional, Marxsen, Bartscht, additional, Derigs, Hans Guenter, additional, Lambertz, Helmut, additional, Becker-Boost, Ingulf, additional, Caca, Karel, additional, Constantin, Christian, additional, Decker, Thomas, additional, Eschenburg, Henning, additional, Gabius, Sigrun, additional, Hebart, Holger, additional, Hoffmeister, Albrecht, additional, Horst, Heinz-August, additional, Kremers, Stephan, additional, Leithaeuser, Malte, additional, Mueller, Sebastian, additional, Wagner, Siegfried, additional, Daum, Severin, additional, Schlegel, Frank, additional, Stauch, Martina, additional, Heinemann, Volker, additional, Maiello, Evaristo, additional, Latini, Luciano, additional, Zaniboni, Alberto, additional, Amadori, Dino, additional, Aprile, Giuseppe, additional, Barni, Sandro, additional, Mattioli, Rodolfo, additional, Martoni, Andrea, additional, Passalacqua, Rodolfo, additional, Nicolini, Mario, additional, Pasquini, Enzo, additional, Rabbi, Carla, additional, Aitini, Enrico, additional, Ravaioli, Alberto, additional, Barone, Carlo, additional, Biasco, Guido, additional, Tamberi, Stefano, additional, Gambi, Angelo, additional, Verusio, Claudio, additional, Marzola, Marina, additional, Lelli, Giorgio, additional, Boni, Corrado, additional, Cascinu, Stefano, additional, Bidoli, Paolo, additional, Vaghi, Massimo, additional, Cruciani, Giorgio, additional, Di Costanzo, Francesco, additional, Sobrero, Alberto, additional, Petrioli, Roberto, additional, Aglietta, Massimo, additional, Alabiso, Oscar, additional, Capuzzo, Federico, additional, Falcone, Alfredo, additional, Corsi, Domenico Cristi, additional, Labianca, Roberto, additional, Salvagni, Stefania, additional, Chiara, Silvana, additional, Ciuffreda, Libero, additional, Ferraù, Francesco, additional, Giuliani, Francesco, additional, Lonardi, Sara, additional, Gebbia, Nicola, additional, Mantovani, Giovanni, additional, Sanches, Evaristo, additional, Mellidez, Juan Carlos, additional, Santos, Pedro, additional, Freire, Joao, additional, Sarmento, Cristina, additional, Costa, Luis, additional, Pinto, Antonio Moreira, additional, Barroso, Sergio, additional, Santo, Jorge Espirito, additional, Guedes, Fátima, additional, Monteiro, Amélia, additional, Sa, Anabela, additional, Furtado, Irene, additional, Salazar, Ramon, additional, Aguilar, Enrique Aranda, additional, Herrero, Fernando Rivera, additional, Valera, Javier Sastre, additional, Ayerbes, Manuel Valladares, additional, Batlle, Jaime Feliu, additional, Gil, Silvia, additional, Esteve, Albert Abad, additional, Garcia-Giron, Carlos, additional, Vivanco, Guillermo Lopez, additional, Salvia, Antonia Salud, additional, Orduña, Vicente Alonso, additional, Garcia, Ruth Vera, additional, Gallego, Javier, additional, Sureda, Bartomeu Massuti, additional, Remon, Jordi, additional, Safont Aguilera, Maria Jose, additional, Nogueras, Luis Cirera, additional, Merino, Bernado Queralt, additional, Castro, Cristina Gravalos, additional, de Prado, Purificacion Martinez, additional, Pericay, Carlos Pijaume, additional, Figueiras, Manuel Constenla, additional, Jordan, Inmaculada Guasch, additional, Gome Reina, Maria Jose, additional, Garcia, Amelia Lopez-Ladron, additional, Garcia-Ramos, Antonio Arrivi, additional, Cervantes, Andres, additional, Martos, Carlos Fernandez, additional, Gaspar, Eugenio Marcuello, additional, Montero, Ines Cabezas, additional, Emperador, Pilar Escudero, additional, Carbonero, Ana Leon, additional, Castillo, Manuel Gallen, additional, Garcia, Teresa Garcia, additional, Lopez, Jose Garcia, additional, Flores, Encarnacion Gonzalez, additional, Morales, Monica Guillot, additional, Muñoz, Marta Llanos, additional, Martín, Ana López, additional, Maurel, Joan, additional, Camara, Juan Carlos, additional, Garcia, Rosario Dueñas, additional, Salgado, Mercedes, additional, Busquier, Isabel Hernandez, additional, Ruiz, Teresa Checa, additional, Muñoa, Adelaida Lacasta, additional, Aliguer, Miquel Nogue, additional, de Taranco, Amalia Velasco Ortiz, additional, Ureña, Miguel Mendez, additional, Gaspa, Ferran Losa, additional, Ponce, Jose Juan, additional, Roig, Carlos Bosch, additional, Jimenez, Pedro Valero, additional, Brotons, Antonio Galan, additional, Rodriguez, Santiago Albiol, additional, Martinez, Jose Ales, additional, Ruiz, Liliana Canosa, additional, Ruiz, Margarita Centelles, additional, Bridgewater, John, additional, Glynne-Jones, Rob, additional, Tahir, Saad, additional, Hickish, Tamas, additional, Cassidy, Jim, additional, and Samuel, Leslie, additional

Published
2017
Full Text
View/download PDF

22. SOX17 Regulates Cholangiocyte Differentiation and Acts as a Tumour Suppressor in Cholangiocarcinoma

Author

Alvaro Santos-Laso, Kristen M. Thelen, M.J. Perugorria, Gregory J. Gores, José Luis Lavín, Nidhi Jalan-Sakrikar, Sergio A. Gradilone, Jose J.G. Marin, O. Erice, Maite G. Fernandez-Barrena, Adelaida Lacasta, Robert C. Huebert, Ana M. Aransay, Maite Merino-Azpitarte, Elisa Lozano, Luis Bujanda, Marco Marzioni, Raul Jimenez-Agüero, and Jesus M. Banales

Subjects
0301 basic medicine, Hepatology, business.industry, Liver tumours, Cholangiocyte, law.invention, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, law, Cancer research, Medicine, Suppressor, 030211 gastroenterology & hepatology, business
Published
2016

23. Correlation between RECIST-criteria, morphologic response by CT and pathologic regression in hepatic metastasis secondary to colorectal cancer: The AVAMET study

Author

M. Jorge, A. Ruiz, M.J. Safont, Adelaida Lacasta, Juan Ramón Ayuso, M. Salgado Fernandez, Carles Pericay, Venancio Martínez, J. M. Campos, Juan De la camara, M. Martin, E. Falcó, P. García-Alfonso, Jorge Aparicio, Jose María Vieitez, M. Marín Vera, C. Montagut, R. Vera, Joan Figueras, and Miquel Gómez

Subjects
Oncology, medicine.medical_specialty, business.industry, Colorectal cancer, Internal medicine, Medicine, Morphologic Response, Hematology, business, medicine.disease, Hepatic metastasis, Regression
Published
2017

24. 2051 Relation between RAS mutations and radiologic (RECIST and morphologic) and pathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study

Author

E. Falcó, R. Vera Garcia, J. M. Campos, Marta Martin-Richard, Juan Ramón Ayuso, Carles Pericay, C. Montagut, M.J. Safont, P. García Alfonso, Juan Carlos Cámara, Veronica Laura Martinez, Adelaida Lacasta, Joan Figueras, M.L. Marín, Arturo Ruiz, Mónica Jorge, Miquel Gómez, Jose María Vieitez, Jorge Aparicio, and M. Salgado

Subjects
Oncology, Cancer Research, Pathology, medicine.medical_specialty, business.industry, Colorectal cancer, Internal medicine, medicine, Pathologic Response, business, medicine.disease, Hepatic metastasis
Published
2015

25. Patterns of local recurrence in rectal cancer after a multidisciplinary approach

Author

Luis Bujanda, José María Enríquez-Navascués, Aintzane Lizerazu, Juan Pablo Ciria, José Luis Elósegui, Nerea Borda, Carlos Placer, and Adelaida Lacasta

Subjects
medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, Anastomosis, Meta-Analysis as Topic, Risk Factors, medicine, Combined Modality Therapy, Humans, Pelvic Neoplasms, Topic Highlight, Pelvis, Clinical Trials as Topic, business.industry, Rectal Neoplasms, Gastroenterology, General Medicine, medicine.disease, Total mesorectal excision, Surgery, Radiation therapy, medicine.anatomical_structure, Lymph Node Excision, Neoplasm Recurrence, Local, business, Chemoradiotherapy
Abstract

Improvements in surgery and the application of combined approaches to fight rectal cancer have succeeded in reducing the local recurrence (LR) rate and when there is LR it tends to appear later and less often in isolation. Moreover, a subtle change in the distribution of LRs with respect to the pelvis has been observed. In general terms, prior to total mesorectal excision the most common LRs were central types (perianastomotic and anterior) while lateral and posterior forms (presacral) have become more common since the growth in the use of combined treatments. No differences have been reported in the current pattern of LRs as a function of the type of approach used, that is, neo-adjuvant therapies (short-term or long-course radiotherapy, or chemoradiotherapy versus extended lymphadenectomy, though there is a trend towards posterior or presacral LR in patients in the Western world and lateral LR in Asia. Nevertheless, both may arise from the same mechanism. Moreover, as well as the mode of treatment, the type of LR is related to the height of the initial tumor. Nowadays most LRs are related to the advanced nature of the disease. Involvement of the circumferential radial margin and spillage of residual tumor cells from lymphatic leakage in the pelvic side wall are two plausible mechanisms for the genesis of LR. The patterns of pelvic recurrence itself (pelvic subsites) also have important implications for prognosis and are related to the potential success of salvage curative approach. The re-operability for cure and prognosis are generally better for anastomotic and anterior types than for presacral and lateral recurrences. Overall survival after LR diagnosis is lower with radio or chemoradiotherapy plus optimal surgery approaches, compared to optimal surgery alone.

Published
2011

26. [Clinicopathological characteristics and survival outcome of esophageal cancer. Results from a series of 200 patients]

Author

Luis, Bujanda, Inés, Gil, Cristina, Sarasqueta, Elisabeth, Hijona, Angel, Cosme, José Luis, Elorza, José Ignacio, Asensio, Santiago, Larburu, Adelaida, Lacasta, Sara, Arévalo, and Julián, Mínguez

Subjects
Male, Survival Rate, Esophageal Neoplasms, Humans, Female, Middle Aged, Prognosis, Aged
Abstract

The esophageal cancer (EC) is a slightly frequent but serious disease. Our aim is to describe the characteristics of the patients with EC in our Hospital.We included 200 patients consecutively diagnosed and/or treated for CE between between January, 2003 and December, 2007. The location of the tumor was analyzed, the histological type, the proofs realized for to establish the classification, the treatments, the survival and the morbi-mortality of the surgery.The endoscopic ultrasonography (EUS) modified the therapeutic strategy in 12% of the patients. The survival to the year, 3 years and 5 years was 48%, 25% and 21%, respectively. 74 (32%) patients were operated, 48 (65%) of them was treated with neoadjuvant chemoradiotherapy. The postsurgical mortality was 8% (6 patients) and the morbidity was 57% (114 patients). In multivariate analysis, after adjustment for traditional risk factors, were the location in the average third ( [HR, hazard ratio]=2.3; confidence interval [IC] of 95%, 1.3-4.1) and not accomplishment of surgery after the chemotherapy and radiotherapy (HR=1.9; IC to 95%, 1.15-3).The diagnosis is realized very later. The EUS has contributed a better therapeutic strategy to our patients. The mortality continues being high.

Published
2009

27. Chemotherapy and radiotherapy in locally advanced cervical cancer

Author

Enrique Delgado, Joan Brunet, Marta Llanos, Josefina Fuentes, Adelaida Lacasta, Josep M. Badia, Luis A. Mendoza, B. Ojeda, and Carmen Alonso

Subjects
Oncology, Adult, medicine.medical_specialty, medicine.medical_treatment, Phases of clinical research, Uterine Cervical Neoplasms, Bleomycin, Disease-Free Survival, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Medicine, Humans, Radiology, Nuclear Medicine and imaging, Survival rate, Melphalan, Survival analysis, Aged, Cervical cancer, Chemotherapy, business.industry, Hematology, General Medicine, Middle Aged, medicine.disease, Carmustine, Surgery, Radiation therapy, Survival Rate, chemistry, Chemotherapy, Adjuvant, Carcinoma, Squamous Cell, Prednisone, Female, business
Abstract

Radiotherapy has been standard therapy for locally advanced squamous cell cervical cancer. Neoadjuvant chemotherapy is being studied to improve responses and survival. We report a phase II study in locally advanced squamous cell cervical cancer (FIGO stages III and IVA) using chemotherapy with bleomycin, methotrexate and cisplatin (BMP) followed by radical radiotherapy. Of the 35 patients, 31 in stage III and 4 in stage IVA, 3 complete responses (CR) and 22 partial responses (PR) were achieved after chemotherapy treatment. Thirty-one patients completed radiotherapy; 19 achieved CR and 4 PR. Five-year actuarial survival for the entire group was 45% (95% confidence interval, 37-53%) with a median survival of 56 months. Patients with CR had a significantly better survival: the 5-year actuarial survival was 74% (95% CI, 59-89%). Recurrence developed in 4 of 19 patients. The most frequent side-effects were nausea and vomiting. Myelosuppression and impaired renal function also occurred. There was no evidence of radiotherapy toxicity enhancement. The stage and Karnofsky index were significant prognostic factors. It is concluded that BMP chemotherapy in advanced cervical cancer is effective and, followed by radiotherapy, allows a good control of this tumor. The group of patients with complete response have a low rate of recurrences and a long survival chance.

Published
1995

30. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

Author

Adelaida Lacasta, Manuel Valladares, R. Dueñas, M.J. Safont, Albert Abad, Andrés Cervantes, Bartomeu Massuti, Antonio Arrivi, Pilar Escudero, Eduardo Díaz-Rubio, Manuel Benavides, Ferran Losa, Antonio Antón, Purificación Martínez de Prado, Amelia López-Ladrón, Jose Tabernero, Eugenio Marcuello, Carlos Fernández-Martos, Javier Sastre, Marta Llanos, Manuel Gallén, Enrique Aranda, Auxiliadora Gómez-España, Fernando Rivera, and Encarnación González

Subjects
Oncology, Male, Cancer Research, medicine.medical_specialty, Bevacizumab, genetic structures, Colorectal cancer, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Capecitabine, chemistry.chemical_compound, Maintenance therapy, Academia-Pharma Intersect, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, business.industry, Induction chemotherapy, medicine.disease, eye diseases, humanities, Oxaliplatin, chemistry, Fluorouracil, Deoxycytidine, Female, sense organs, business, Colorectal Neoplasms, medicine.drug
Abstract

Purpose. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with metastatic colorectal cancer (mCRC). Patients and Methods. Patients were randomly assigned to receive six cycles of bevacizumab, capecitabine, and oxaliplatin every 3 weeks followed by XELOX plus bevacizumab or bevacizumab alone until progression. The primary endpoint was the progression-free survival (PFS) interval; secondary endpoints were the overall survival (OS) time, objective response rate (RR), time to response, duration of response, and safety. Results. The intent-to-treat population comprised 480 patients (XELOX plus bevacizumab, n = 239; bevacizumab, n = 241); there were no significant differences in baseline characteristics. The median follow-up was 29.0 months (range, 0–53.2 months). There were no statistically significant differences in the median PFS or OS times or in the RR between the two arms. The most common grade 3 or 4 toxicities in the XELOX plus bevacizumab versus bevacizumab arms were diarrhea, hand–foot syndrome, and neuropathy. Conclusion. Although the noninferiority of bevacizumab versus XELOX plus bevacizumab cannot be confirmed, we can reliably exclude a median PFS detriment >3 weeks. This study suggests that maintenance therapy with single-agent bevacizumab may be an appropriate option following induction XELOX plus bevacizumab in mCRC patients.

31. Multiple primary tumors and familial cancers. A case report

Author

Mariano Provencio, Pilar España, Félix Bonilla, José M. Lopez-Vega, and Adelaida Lacasta

Subjects
Male, Oncology, Cancer Research, medicine.medical_specialty, Primary (chemistry), business.industry, Retinoblastoma, Cancer, General Medicine, Middle Aged, medicine.disease, Pedigree, Neoplasms, Multiple Primary, Neoplasms, Internal medicine, medicine, Humans, business
Abstract

We herein report the case of a patient who had 4 primary tumors, 3 of which were malignant. His family had a high rate (26 %) of cancer. The possible genetic factors that can produce these events are briefly discussed.

Catalog

Books, media, physical & digital resources
See catalog results